Co-transplantation of olfactory ensheathing glia and mesenchymal stromal cells	1
Co-transplantation	1
olfactory ensheathing glia and mesenchymal stromal cells	23
olfactory ensheathing glia	23
mesenchymal stromal cells	54
synergistic effects	94
spinal cord injury in the rat TAKASHI AMEMORI1	120
spinal cord injury	120
the rat TAKASHI AMEMORI1	142
PAVLA JENDELOVÁ1 ,2	168
PAVLA JENDELOVÁ1	168
,2	184
KATERˇ INA RU ° ŽICˇKOVÁ1	188
KATERˇ INA	188
RU ° ŽICˇKOVÁ1	199
DAVID ARBOLEDA1 & EVA SYKOVÁ1 ,2 1Institute of Experimental Medicine	214
DAVID ARBOLEDA1 & EVA SYKOVÁ1	214
,2 1Institute of Experimental Medicine	243
,2 1Institute	243
Experimental Medicine	260
Academy of Sciences of the Czech Republic	283
Academy	283
Sciences of the Czech Republic	294
Sciences	294
the Czech Republic	306
Prague , Czech Republic	326
Prague	326
Czech Republic	334
2Department	354
Neuroscience and Center	369
Cell Therapy and Tissue Repair	397
Charles University	429
2nd Medical Faculty	449
Prague	470
Czech Republic Abstract Background	478
Olfactory ensheathing glia -LRB- OEG -RRB-	519
Olfactory ensheathing glia	519
OEG	547
mesenchymal stromal cells -LRB- MSC -RRB-	556
mesenchymal stromal cells	556
MSC	583
suitable candidates	592
transplantation therapy of spinal cord injury -LRB- SCI -RRB-	616
transplantation therapy	616
spinal cord injury -LRB- SCI -RRB-	643
spinal cord injury	643
SCI	663
Both	669
functional improvement	685
SCI	714
trophic factors and cytokines	731
this study	765
the co-transplantation of both types of cells	777
the co-transplantation	777
both types of cells	803
both types	803
cells	817
their additive and / or synergistic effects on SCI	846
their additive	846
synergistic effects on	869
synergistic effects	869
SCI	892
Methods .	897
A balloon-induced compression lesion	906
SCI in rats	963
SCI	963
rats	970
OEG , MSC or both OEG and MSC -LRB- 3 × 105 cells of each cell type -RRB-	976
OEG , MSC or both OEG and MSC	976
OEG	976
MSC	981
both OEG and MSC	988
3 × 105 cells of each cell type	1006
3 ×	1006
105 cells of each cell type	1010
105 cells	1010
each cell type	1023
intraspinal injection	1057
1 week	1079
SCI	1092
The effect of transplantation	1097
The effect	1097
transplantation	1111
behavioral , electrophysiologic and histologic methods	1146
Results .	1201
Hindlimb function	1210
Basso , Beattie and Bresnahan -LRB- BBB -RRB- and Plantar tests	1246
Basso , Beattie and Bresnahan -LRB- BBB -RRB-	1246
Basso , Beattie and Bresnahan	1246
BBB	1276
Plantar tests	1285
Improvement	1300
all three groups of transplanted rats with different time -- courses	1325
all three groups	1325
transplanted rats with different time -- courses	1345
transplanted rats	1345
different time -- courses	1368
different time	1368
courses	1383
there	1396
no signifi cant difference among the groups at the end of the experiment	1406
no signifi cant difference	1406
the groups at the end of the experiment	1439
the groups	1439
the end of the experiment	1453
the end	1453
the experiment	1464
Motor-evoked potentials after SCI	1480
Motor-evoked potentials	1480
SCI	1510
amplitude	1527
7 mV	1542
10 μV	1550
Linear regression analysis	1557
a modest recovery	1591
amplitude following transplantation , but no change in the control rats	1612
amplitude following transplantation	1612
amplitude	1612
transplantation	1632
no change in the control rats	1653
no change	1653
the control rats	1666
Histologic fi ndings	1684
the white and gray matter	1717
transplantation	1773
SCI	1795
Conclusions .	1800
Functional improvement	1813
transplantation of OEG and/or MSC	1854
transplantation	1854
OEG and/or MSC	1873
OEG	1873
MSC	1884
the co-transplantation of OEG and MSC	1893
the co-transplantation	1893
OEG and MSC	1919
synergistic effects	1944
The poor migration of OEG and MSC	1965
The poor migration	1965
OEG and MSC	1987
their concerted action	2013
Pre-treatment with a Rho antagonist	2037
Pre-treatment	2037
a Rho antagonist	2056
a combination of intraspinal and intravenous injection of the cells	2077
a combination	2077
intraspinal and intravenous injection	2094
the cells	2135
benefi cial for SCI therapy	2154
SCI	2170
Introduction Cell therapy	2184
a promising approach	2213
locomotor function	2247
spinal cord injury -LRB- SCI -RRB-	2272
spinal cord injury	2272
SCI	2292
Both olfactory ensheathing glia -LRB- OEG -RRB-	2298
Both olfactory ensheathing glia	2298
OEG	2331
mesenchymal stromal cells -LRB- MSC -RRB-	2340
mesenchymal stromal cells	2340
MSC	2367
promising candidates for cell therapy	2410
promising candidates	2410
cell therapy	2435
The implantation of OEG	2449
The implantation	2449
OEG	2469
cavity and scar formation	2494
astrocytes	2534
angiogenesis and myelination -LRB- 1,2 -RRB-	2559
angiogenesis and myelination	2559
1,2	2589
OEG	2595
the levels	2608
chondroitin sulfate proteoglycan -LRB- CSPG -RRB-	2622
chondroitin sulfate proteoglycan	2622
CSPG	2656
inhibitory effects on growing axons following SCI -LRB- 3,4 -RRB-	2673
inhibitory effects	2673
growing axons following SCI -LRB- 3,4 -RRB-	2695
growing axons	2695
SCI -LRB- 3,4 -RRB-	2719
SCI	2719
3,4	2724
OEG	2735
a permissive environment	2755
axons	2808
injury	2820
growth factors	2840
NGF , BDNF , GDNF and VEGF	2856
NGF	2856
BDNF , GDNF and VEGF	2861
extracellular matrix molecules -LRB- collagen , laminin and fi bronectin -RRB-	2886
extracellular matrix molecules	2886
collagen , laminin and fi bronectin	2918
addition	2957
adhesion molecules -LRB- 5 -- 7 -RRB-	2969
adhesion molecules	2969
5 -- 7	2989
5	2989
7	2991
OEG display phenotypes of both Schwann cells and astrocytes .	2995
OEG display phenotypes	2995
both Schwann cells and astrocytes	3021
They	3056
Schwann cells	3087
astrocytes	3106
astrocytes	3122
OEG	3153
oligodendrocytes -LRB- 8 -RRB-	3165
oligodendrocytes	3165
8	3183
These characteristic features of OEG	3187
These characteristic features	3187
OEG	3220
the ingrowth of axons from the peripheral nervous system -LRB- PNS -RRB-	3232
the ingrowth	3232
axons from the peripheral nervous system -LRB- PNS -RRB-	3248
axons	3248
the peripheral nervous system -LRB- PNS -RRB-	3259
the peripheral nervous system	3259
PNS	3290
the central nervous system -LRB- CNS -RRB-	3298
the central nervous system	3298
CNS	3326
the laminin-rich boundary established following SCI	3338
the laminin-rich boundary	3338
SCI	3386
9	3391
Au et al. -LRB- 10 -RRB-	3395
Au et al.	3395
Au	3395
et al.	3398
10	3406
the production of	3426
the production	3426
protein acidic	3453
cysteine -LRB- SPARC -RRB-	3476
cysteine	3476
SPARC	3486
OEG regulated laminin-1 production	3496
OEG	3496
laminin-1 production	3510
Schwann cells and astrocytes	3543
the re-entry of regenerating axons into the CNS	3598
the re-entry	3598
axons	3627
the CNS	3638
MSC	3647
multipotent progenitor cells	3655
the case of severe tissue ischemia or damage	3693
the case	3693
severe tissue ischemia or damage	3705
the lesion site , where they can secrete cytokines	3759
the lesion site	3759
they	3782
cytokines	3799
interleukins	3810
trophic factors	3828
an inhibitory infl uence	3859
scarring and apoptosis	3887
They	3911
angiogenesis and neural regeneration -LRB- 11 -RRB-	3927
angiogenesis and neural regeneration	3927
11	3965
the bone marrow -LRB- BM -RRB-	3985
the bone marrow	3985
BM	4002
culture	4033
MSC	4042
the damaged site	4066
direct or systemic application	4086
Functional improvement resulting from MSC transplantation	4118
Functional improvement	4118
MSC transplantation	4156
their neuroprotective and reconstructive infl uences	4208
the lesion site	4264
their secretion of various trophic factors such as cytokines and growth factors	4296
their secretion	4296
various trophic factors such as cytokines and growth factors	4315
various trophic factors	4315
cytokines and growth factors	4347
12 -- 14	4377
12	4377
14	4380
their down-regulation of caspase	4388
their down-regulation	4388
caspase	4413
3 , which mediates apoptosis -LRB- 15 -RRB- ,	4422
3	4422
apoptosis -LRB- 15 -RRB-	4440
apoptosis	4440
15	4451
their immunomodulatory and anti-apoptotic activity	4468
their production	4534
galectin-1 , angiopoietin - 1 , osteopontin and thrombospondin-1 and -2	4554
galectin-1 , angiopoietin	4554
galectin-1	4554
angiopoietin	4566
1 , osteopontin and thrombospondin-1 and -2	4580
1	4580
osteopontin and thrombospondin-1	4583
-2	4620
16,17	4624
functional recovery	4647
SCI	4673
18 -- 20	4678
18	4678
20	4681
Their easy accessibility and rapid expansion in culture	4686
Their easy accessibility and rapid expansion	4686
culture	4734
attractive characteristics from a therapeutic point of view	4746
attractive characteristics	4746
a therapeutic point of view	4778
a therapeutic point	4778
view	4801
The co-transplantation of OEG and MSC	4807
The co-transplantation	4807
OEG and MSC	4833
benefi cial for SCI treatment	4852
SCI	4868
a combinatory approach	4890
OEG	4914
regeneration	4933
SCI	4956
guiding strands and molecules of the extracellular matrix for axonal ingrowth	4973
guiding strands and molecules	4973
the extracellular matrix for axonal ingrowth	5006
the extracellular matrix	5006
axonal ingrowth	5035
other cell types such as MSC	5058
other cell types	5058
MSC	5083
functional outcome	5099
trophic factors and cytokines	5131
addition	5165
OEG as well as MSC	5175
OEG	5175
MSC	5190
autologous transplantation protocols	5209
no additional immunosuppression	5261
this study	5316
the effect	5328
the transplantation of OEG , MSC	5342
the transplantation	5342
OEG , MSC	5365
the co-transplantation	5378
both OEG and MSC	5404
OEG	5409
MSC	5417
behavioral , electrophysiologic and histologic outcomes	5424
SCI	5485
Methods Adult male Wistar rats	5503
Methods	5503
Adult male Wistar rats	5511
270	5543
300 g	5547
our experiments	5566
The lesioned animals	5583
four groups	5622
The fi rst group	5635
both OEG and MSC -LRB- n = 21 -RRB-	5661
both OEG and MSC	5661
OEG	5666
MSC	5674
n	5679
21	5683
The second and third groups	5688
only OEG -LRB- n = 22 -RRB- or MSC -LRB- n = 23 -RRB-	5739
only OEG	5739
n	5749
22	5753
MSC	5760
n	5765
23	5769
The fourth group	5788
saline	5823
a control -LRB- n = 23 -RRB-	5833
a control	5833
n	5844
23	5848
All experiments	5853
accordance	5887
the European Communities Council Directive	5903
24th	5949
November 1986 -LRB- 86/609/EEC -RRB- regarding the use of animals in research	5957
November 1986 -LRB- 86/609/EEC -RRB-	5957
November 1986	5957
86/609/EEC	5972
the use of animals in research	5994
the use	5994
animals in research	6005
animals	6005
research	6016
the Ethics Committee of the Institute of Experimental Medicine ASCR , Prague ,	6047
the Ethics Committee	6047
the Institute of Experimental Medicine ASCR , Prague ,	6071
the Institute	6071
Experimental Medicine ASCR , Prague ,	6088
Experimental Medicine ASCR	6088
Prague	6116
Czech Republic	6124
SCI Balloon compression	6140
an SCI	6183
A small opening of the thoracic vertebra 10 -LRB- T10 -RRB-	6191
A small opening	6191
the thoracic vertebra 10 -LRB- T10 -RRB-	6210
the thoracic vertebra 10	6210
T10	6236
A 2-french Fogarty catheter	6256
T8	6303
the balloon	6311
15 μL saline for 5 min at T8 -LRB- 19,21 -RRB-	6342
15 μL saline	6342
5 min at T8 -LRB- 19,21 -RRB-	6359
5 min	6359
T8 -LRB- 19,21 -RRB-	6368
T8	6368
19,21	6372
the surgical procedure	6387
the body temperature of the animal	6411
the body temperature	6411
the animal	6435
37 °C with a heating pad	6464
37 °C	6464
a heating pad	6474
3 % isofl urane in air	6493
3 % isofl urane	6493
air	6511
a fl ow rate of 0.3 L/min	6535
a fl ow rate	6535
0.3 L/min	6551
edema development	6572
a result of low levels of anesthesia -LRB- 22 -RRB-	6593
a result	6593
low levels of anesthesia -LRB- 22 -RRB-	6605
low levels	6605
anesthesia -LRB- 22 -RRB-	6619
anesthesia	6619
22	6631
the lesioning procedure	6646
the rats	6671
feeding and urination	6697
they	6725
these functions	6769
their own	6788
The animals	6799
gentamicin sulfate -LRB- 5 mg/kg -RRB- for 3 days	6820
gentamicin sulfate -LRB- 5 mg/kg -RRB-	6820
gentamicin sulfate	6820
5 mg/kg	6840
3 days	6853
post-operative infections	6871
OEG preparation and identifi cation OEG	6898
OEG preparation	6898
identifi cation OEG	6918
4-week-old Wistar rats	6957
The olfactory mucosa	6981
both sides of the nasal septum	7019
both sides	7019
the nasal septum	7033
incubation in Dispase II -LRB- Roche , Mannheim , Germany -RRB-	7057
incubation	7057
Dispase II -LRB- Roche , Mannheim , Germany -RRB-	7071
Dispase II	7071
Roche	7083
Mannheim	7090
Germany	7100
the lamina propria	7110
the epithelium	7161
collagenase type I -LRB- Sigma , St. Louis , MO , USA -RRB- -LRB- 23 -RRB-	7197
collagenase type I -LRB- Sigma , St. Louis , MO , USA -RRB-	7197
collagenase type I	7197
collagenase type	7197
I	7214
Sigma	7217
St. Louis	7224
MO , USA	7235
23	7245
a 24-h incubation in Dulbecco 's modifi	7256
a 24-h incubation	7256
Dulbecco 's modifi	7277
Dulbecco 's	7277
Eagle medium -LRB- DMEM -RRB- / F12 with 10 % fetal bovine serum	7298
Eagle medium -LRB- DMEM -RRB-	7298
Eagle medium	7298
DMEM	7312
F12 with 10 % fetal bovine serum	7318
F12	7318
10 % fetal bovine serum	7327
the cells	7351
5 × 10	7411
5 ×	7411
10	7415
5 M ; Sigma	7418
5 M	7418
Sigma	7423
cells , such as fi broblasts ,	7460
cells	7460
fi broblasts	7475
bovine pituitary extract -LRB- 100 μg/mL ; Sigma -RRB- -LRB- 24 -RRB-	7507
bovine pituitary extract -LRB- 100 μg/mL ; Sigma -RRB-	7507
bovine pituitary extract	7507
100 μg/mL ; Sigma	7533
100 μg/mL	7533
Sigma	7544
24	7552
the purity of OEG cultures , cultured cells on glass slides	7567
the purity	7567
OEG cultures , cultured cells on glass slides	7581
OEG cultures	7581
cells	7604
glass slides	7613
4 % paraformaldehyde , permeabilized in 0.1 % Triton X-100	7641
4 % paraformaldehyde	7641
permeabilized in 0.1 % Triton X-100	7662
0.1 %	7679
serum	7709
primary antibodies	7735
overnight at 4 °C	7754
overnight	7754
4 °C	7767
Two antibodies	7772
OEG : mouse anti-p75	7809
OEG	7809
mouse anti-p75	7814
low-affi nity nerve	7830
growth factor receptor -LRB- 1:100 ; Chemicon , Temecula , CA , USA -RRB-	7850
growth factor receptor	7850
1:100 ; Chemicon , Temecula , CA , USA	7874
1:100	7874
Chemicon , Temecula , CA , USA	7881
rabbit anti-S100 -LRB- 1:200 ; Sigma -RRB-	7915
rabbit anti-S100	7915
1:200 ; Sigma	7933
1:200	7933
Sigma	7940
Alexa Fluor 488-conjugated goat anti-mouse IgG	7948
Alexa Fluor	7948
488-conjugated goat anti-mouse IgG	7960
Alexa Fluor	7999
594-conjugated goat anti-rabbit IgG secondary antibodies -LRB- Sigma -RRB-	8011
594-conjugated goat anti-rabbit IgG secondary antibodies	8011
Sigma	8069
the two primary antibodies	8101
cells	8137
a fl	8160
uorescent microscope -LRB- Zeiss Axioskop , Göttingen , Germany -RRB-	8165
uorescent microscope	8165
Zeiss Axioskop	8187
Göttingen	8203
Germany	8214
More than 80 % of cultured cells	8224
More than 80 %	8224
cells	8250
MSC preparation BM	8280
the tibia and femur of 4-week-old Wistar rats	8318
the tibia and femur	8318
4-week-old Wistar rats	8341
fl ushing	8367
DMEM	8382
BM cells	8388
DMEM medium	8441
10 % fetal bovine serum	8471
100 U/mL penicillin	8495
0.1 mg/mL streptomycin -LRB- Gibco -RRB-	8519
0.1 mg/mL streptomycin	8519
Gibco	8543
MSC	8551
their adherence	8577
plastic	8596
a 24-h incubation	8611
non-adherent cells , including hematopoietic stem cells ,	8630
non-adherent cells	8630
hematopoietic stem cells	8660
the medium -LRB- 19,25 -RRB-	8712
the medium	8712
19,25	8724
MSC	8732
transplantation	8750
6	8772
10 passages	8774
Transplantation The animals	8787
Transplantation	8787
The animals	8803
transplanted 1 week	8820
SCI	8846
transplantation , OEG	8863
transplantation	8863
OEG	8880
the fl uorescent	8902
10 μM carboxy-fl uorescein	8923
diacetate succinimidyl ester	8950
CFDA-SE ; green fl uorescence ; Molecular Probes , Eugene , OR , USA	8980
CFDA-SE	8980
green fl uorescence ; Molecular Probes , Eugene , OR , USA	8989
green fl uorescence	8989
Molecular Probes , Eugene , OR , USA	9010
Molecular Probes	9010
Eugene	9028
OR	9036
USA	9040
MSC	9052
20 μM carboxy SNARF-1	9074
red fl uorescence ; Molecular Probes	9097
red fl uorescence	9097
Molecular Probes	9116
CFDA-SE	9137
subsequent identifi cation of transplanted cells	9156
subsequent identifi cation	9156
transplanted cells	9186
the manufacturer 's instructions	9242
the manufacturer 's	9242
the concentrations of the tracers	9279
the concentrations	9279
the tracers	9301
the results of Imaizumi et al. -LRB- 26 -RRB- and Li et al. -LRB- 27 -RRB-	9327
the results	9327
Imaizumi et al. -LRB- 26 -RRB- and Li et al. -LRB- 27 -RRB-	9342
Imaizumi et al. -LRB- 26 -RRB-	9342
Imaizumi	9342
et al. -LRB- 26 -RRB-	9351
et al.	9351
26	9359
Li et al. -LRB- 27 -RRB-	9367
Li	9367
et al. -LRB- 27 -RRB-	9370
et al.	9370
27	9378
The animals	9383
a stereotaxic apparatus	9411
the spinal process	9446
the injured site of the spinal cord with a ratspecifi c vertebra holder	9482
the injured site	9482
the spinal cord with a ratspecifi c vertebra holder	9502
the spinal cord	9502
a ratspecifi c vertebra holder	9523
Cunningham spinal adaptor ; Stoelting Co.	9555
Cunningham spinal adaptor	9555
Stoelting Co.	9582
Wood Dale , IL , USA	9597
Wood Dale	9597
IL	9608
USA	9612
The spinal cord	9618
T8	9649
A total of 3 × 105 OEG and/or MSC	9653
A total	9653
3 × 105 OEG and/or MSC	9664
3 ×	9664
105 OEG and/or MSC	9668
105 OEG	9668
MSC	9683
a glass pipette	9708
a concentration of 1 × 105 cells/μL	9727
a concentration	9727
1 × 105 cells/μL	9746
1 ×	9746
105 cells/μL	9750
the proximal , central and distal parts	9769
the lesioned spinal cord	9811
each part	9837
1 μL cell suspension	9856
a depth of 1 mm below the dorsal surface	9882
a depth	9882
1 mm below the dorsal surface	9893
1 mm	9893
the dorsal surface	9904
a rate of 1 μL/min using a Nano - Injector -LRB- Stoelting Co. -RRB-	9927
a rate of 1 μL/min using a Nano	9927
a rate	9927
1 μL/min using a Nano	9937
1 μL/min	9937
a Nano	9952
Injector -LRB- Stoelting Co. -RRB-	9960
Injector	9960
Stoelting Co.	9970
OEG/MSC-transplanted animals	9986
six injections	10024
3 × 105 OEG and 3 × 105 MSC	10040
3 × 105 OEG	10040
3 ×	10040
105 OEG	10044
3 × 105 MSC	10056
3 ×	10056
105 MSC	10060
the three injections received by the other animals	10080
the three injections	10080
the other animals	10113
The glass pipette	10132
place	10162
each injection for a further minute	10174
each injection	10174
a further minute	10193
leakage of the cell suspension	10221
leakage	10221
the cell suspension	10232
The control group	10253
three injections of saline -LRB- 1 μL/injection -RRB-	10280
three injections	10280
saline	10300
1 μL/injection	10308
the proximal , central and distal parts of the lesioned spinal cord	10335
the proximal , central and distal parts	10335
the lesioned spinal cord	10377
Cyclosporine -LRB- 10 mg/kg -RRB- and ampicillin -LRB- 50 -- 100 mg / kg -RRB-	10403
Cyclosporine -LRB- 10 mg/kg -RRB-	10403
Cyclosporine	10403
10 mg/kg	10417
ampicillin -LRB- 50 -- 100 mg / kg -RRB-	10431
ampicillin	10431
50 -- 100 mg / kg	10443
50	10443
100 mg	10446
kg	10454
1 day	10494
transplantation	10507
the experiment	10538
2 months	10558
OEG and MSC	10569
green fl uorescent protein transgenic rats	10586
easily distinguishable and stable tracking of transplanted cells	10644
easily distinguishable and stable tracking	10644
transplanted cells	10690
OEG and MSC expressing	10710
green fl uorescent protein -LRB- GFP -RRB- isolated from GFP + rats	10742
green fl uorescent protein -LRB- GFP -RRB-	10742
green fl uorescent protein	10742
GFP	10770
GFP + rats	10789
GFP	10789
rats	10794
2-month survival experiments	10812
Transgenic Sprague	10842
Dawley rats -LRB- SD-Tg -LRB- CAG-EGFP -RRB- CZ-004Osb -RRB-	10861
Dawley rats	10861
SD-Tg -LRB- CAG-EGFP -RRB- CZ-004Osb	10874
SD-Tg -LRB- CAG-EGFP -RRB-	10874
SD-Tg	10874
CAG-EGFP	10880
CZ-004Osb	10889
Dr Masaru Okabe -LRB- Osaka University , Osaka , Japan -RRB- -LRB- 28 -RRB-	10924
Dr Masaru Okabe -LRB- Osaka University , Osaka , Japan -RRB-	10924
Dr Masaru Okabe	10924
Osaka University	10941
Osaka	10959
Japan	10966
28	10974
the laboratory	10987
Dr Martin Marsala -LRB- University of California , San Diego , CA , USA -RRB-	11005
Dr Martin Marsala	11005
University of California	11024
University	11024
California	11038
San Diego , CA , USA	11050
San Diego	11050
CA , USA	11061
our institute	11095
our animal facility	11121
Functional analysis	11142
Hindlimb locomotor activity	11162
SCI	11196
the Basso , Beattie and Bresnahan -LRB- BBB -RRB- test -LRB- 29 -RRB-	11216
the Basso , Beattie and Bresnahan -LRB- BBB -RRB- test	11216
Basso , Beattie and Bresnahan -LRB- BBB -RRB-	11220
Basso , Beattie and Bresnahan	11220
BBB	11250
29	11261
OEG/MSC , n = 14 ; OEG , n = 15 ; MSC , n = 16 ; control , n = 12	11266
OEG/MSC	11266
n = 14 ; OEG , n = 15 ; MSC , n = 16 ; control , n = 12	11275
n = 14	11275
n	11275
14	11279
OEG , n = 15	11283
OEG	11283
n = 15	11288
n	11288
15	11292
MSC , n = 16	11296
MSC	11296
n = 16	11301
n	11301
16	11305
control , n = 12	11309
control	11309
n = 12	11318
n	11318
12	11322
The rats	11327
a fl oor within a circular enclosure	11351
a fl oor	11351
a circular enclosure	11367
Basso	11404
et al. -LRB- 29 -RRB-	11410
et al.	11410
29	11418
Their hindlimb joint movement	11423
paw placement , weight support , forelimb -- hindlimb co-ordination , etc.	11454
paw placement	11454
weight support , forelimb -- hindlimb co-ordination	11469
weight support , forelimb	11469
weight support	11469
hindlimb co-ordination	11494
a 0 -- 21-point scale	11545
a 0	11545
21-point scale	11549
Hindpaw withdrawal latency to a noxious thermal stimuli	11565
Hindpaw withdrawal latency	11565
a noxious thermal stimuli	11595
a Plantar test apparatus -LRB- Ugo Basile , Comerio , Italy -RRB-	11639
a Plantar test apparatus	11639
Ugo Basile	11665
Comerio	11677
Italy	11686
OEG/MSC , n = 10 ; OEG , n = 10 ; MSC , n = 10 ; control , n = 10	11694
OEG/MSC	11694
n = 10 ; OEG , n = 10 ; MSC , n = 10 ; control , n = 10	11703
n = 10	11703
n	11703
10	11707
OEG , n = 10	11711
OEG	11711
n = 10	11716
n	11716
10	11720
MSC , n = 10	11724
MSC	11724
n = 10	11729
n	11729
10	11733
control , n = 10	11737
control	11737
n = 10	11746
n	11746
10	11750
The animals	11755
a clear plastic chamber	11782
10 min	11825
quiescent	11847
The hindpaw	11858
a heat stimulus	11879
a glass plate	11903
The withdrawal latencies	11918
three times	11957
each hindpaw at 5-min intervals	11973
each hindpaw	11973
5-min intervals	11989
The average of three values	12006
The average	12006
three values	12021
statistical evaluation	12047
Motor-evoked potentials Rats	12071
ketamine -LRB- 100 mg/kg -RRB-	12123
ketamine	12123
100 mg/kg	12133
One pair of needle electrodes	12145
One pair	12145
needle electrodes	12157
the skull for cortical stimulation	12206
the skull	12206
cortical stimulation	12220
another pair in the gastrocnemius muscle for recording	12245
another pair	12245
the gastrocnemius muscle for recording	12261
the gastrocnemius muscle	12261
recording	12290
The signals	12301
fi ltered -LRB- 1 -- 5000 Hz -RRB-	12318
fi	12318
1 -- 5000 Hz	12329
1	12329
5000 Hz	12331
a Medelec Synergy T-EP EMG/EP Monitoring System	12356
Oxford Instruments Medical Inc.	12405
Surrey	12438
UK	12446
Motor-evoked potentials -LRB- MEP -RRB-	12451
Motor-evoked potentials	12451
MEP	12476
once a week	12495
transcranial stimulation	12510
a single square-pulse electrical stimulus of 0.1 ms in duration	12536
a single square-pulse electrical stimulus	12536
0.1 ms in duration	12581
0.1 ms	12581
duration	12591
the amplitude	12612
latency	12627
onset and duration	12638
the response	12660
OEG/MSC , n = 9 ; OEG , n = 10 ; MSC , n = 11 ; control , n = 7	12674
OEG/MSC	12674
n = 9 ; OEG , n = 10 ; MSC , n = 11 ; control , n = 7	12683
n = 9	12683
n	12683
9	12687
OEG , n = 10	12690
OEG	12690
n = 10	12695
n	12695
10	12699
MSC , n = 11	12703
MSC	12703
n = 11	12708
n	12708
11	12712
control , n = 7	12716
control	12716
n = 7	12725
n	12725
7	12729
the number of transplanted GFP cells	12762
the number	12762
transplanted GFP cells	12776
the possible neural differentiation of the transplanted cells	12811
the possible neural differentiation	12811
the transplanted cells	12850
longitudinal cryostat sections -LRB- 40-μm thickness -RRB- of the spinal cord	12874
longitudinal cryostat sections -LRB- 40-μm thickness -RRB-	12874
longitudinal cryostat sections	12874
40-μm thickness	12906
the spinal cord	12926
4 % paraformaldehyde fi xation	12958
4 %	12958
paraformaldehyde fi xation	12961
Every sixth section	12989
imaging	13024
a fl uorescent microscope	13038
The surviving cells	13065
each section	13101
the total number of cells	13119
the total number	13119
cells	13139
the volume of the section in which the cells were found	13172
the volume	13172
the section in which the cells were found	13186
the section	13186
the cells	13207
The percentage of surviving transplanted cells	13229
The percentage	13229
transplanted cells	13257
the estimated total number of surviving cells	13303
the estimated total number	13303
surviving cells	13333
the total number of transplanted cells -LRB- 3 × 105 cells/rat -RRB-	13352
the total number	13352
transplanted cells -LRB- 3 × 105 cells/rat -RRB-	13372
transplanted cells	13372
3 × 105 cells/rat	13392
3 ×	13392
105 cells/rat	13396
immunohistochemistry	13416
the sections	13438
1 % bovine serum albumin	13469
antibodies	13514
neural markers	13533
1:2500 ; Chemicon	13562
1:2500	13562
Chemicon	13570
1:400 ; Sigma	13602
1:400	13602
Sigma	13609
4 °C	13629
incubation	13646
the Alexa Fluor 594-conjugated secondary antibody	13662
axon tracts	13741
SCI	13759
the corticospinal tract	13764
one of the major descending tracts in the spinal cord	13789
one	13789
the major descending tracts in the spinal cord	13796
the major descending tracts	13796
the spinal cord	13827
Two weeks	13871
termination of the experiment	13888
termination	13888
the experiment	13903
1 μL	13919
a 10 % biotinylated dextran amine -LRB- BDA ; 10 000 MW ; Molecular Probes -RRB-	13927
a 10 %	13927
dextran amine -LRB- BDA ; 10 000 MW ; Molecular Probes -RRB-	13946
dextran amine	13946
BDA	13961
10 000 MW ; Molecular Probes	13966
10 000 MW	13966
Molecular Probes	13977
the sensorimotor cortex	14025
a depth of 1.5 mm	14052
a depth	14052
1.5 mm	14063
the surface with a glass micropipette	14075
the surface	14075
a glass micropipette	14092
BDA-injected animals	14114
ketamine -LRB- 100 mg/kg -RRB- and xylazine -LRB- 20 mg/kg -RRB-	14166
ketamine	14166
100 mg/kg	14176
xylazine	14191
20 mg/kg	14201
their chests	14212
transcardial perfusion	14236
phosphate buffer followed by 4 % paraformaldehyde solution in phosphate buffer	14274
phosphate buffer	14274
4 % paraformaldehyde solution in phosphate buffer	14303
4 % paraformaldehyde solution	14303
phosphate buffer	14335
The spinal column	14353
paraformaldehyde solution overnight	14395
paraformaldehyde solution	14395
The spinal cord	14432
the spinal cord channel and post-fi xed in the same solution for at least 1 week	14480
the spinal cord channel	14480
post-fi xed in the same solution for at least 1 week	14508
post-fi	14508
the same solution for at least 1	14523
the same solution	14523
at least 1	14545
week	14556
An approximately 5-cm long segment from the same area of each spinal cord	14562
An approximately 5-cm long segment	14562
the same area of each spinal cord	14602
the same area	14602
each spinal cord	14619
14-μm thick sagittal frozen sections	14655
the BDA-injected corticospinal tract axons	14715
cryostat sections	14759
avidin horseradish peroxidase	14797
diaminobenzidine	14831
DAB	14849
the instructions in the BDA neuronal tracer kit -LRB- Molecular Probes -RRB-	14865
the instructions	14865
the BDA neuronal tracer kit -LRB- Molecular Probes -RRB-	14885
the BDA neuronal tracer kit	14885
Molecular Probes	14914
Some sections	14933
hematoxylin-eosin	14965
Spinal compression	14984
the formation of cavities within the spinal cord tissue	15014
the formation	15014
cavities within the spinal cord tissue	15031
cavities	15031
the spinal cord tissue	15047
degeneration of the spinal cord	15082
degeneration	15082
the spinal cord	15098
The volume of the spared white and gray matter	15115
The volume	15115
the spared white and gray matter	15129
the end of the experiment	15178
the end	15178
the experiment	15189
perfusion with 4 % paraformaldehyde	15211
perfusion	15211
4 % paraformaldehyde	15226
a 2-cm long segment of the spinal cord	15247
a 2-cm long segment	15247
the spinal cord	15270
1-cm cranial and 1-cm caudal	15308
the injury epicenter	15340
Serial cross-sections -LRB- 5 μm thick -RRB-	15362
Serial cross-sections	15362
5 μm	15385
paraffi n embedding	15413
paraffi n	15413
Luxol-fast blue and Cresyl violet	15450
the white and gray matter	15499
volumetric measurements	15530
six sections	15555
1-mm intervals along the cranio-caudal axis	15585
1-mm intervals	15585
the cranio-caudal axis	15606
whole images of the spinal cord	15634
whole images	15634
the spinal cord	15650
an Axioskop 2 plus microscope -LRB- Zeiss -RRB-	15682
an Axioskop 2	15682
microscope -LRB- Zeiss -RRB-	15701
microscope	15701
Zeiss	15713
ImageJ software	15736
Wayne Rasband , National Institutes of Health , Bethesda , MD , USA	15753
Wayne Rasband	15753
National Institutes of Health , Bethesda , MD	15768
National Institutes	15768
Health , Bethesda , MD	15791
USA	15813
19	15819
Statistical analysis The data	15824
Statistical analysis	15824
The data	15845
mean ± SEM	15871
A one-way analysis	15883
variance	15905
ANOVA	15915
Tukey 's posthoc test	15934
Tukey 's	15934
differences between groups	15976
differences	15976
groups	15996
Regression analyzes	16004
MEP	16041
A P-value < 0.05	16046
A P-value <	16046
0.05	16058
statistically signifi cant	16078
Results Figure 1 .	16107
Results	16107
Figure 1	16115
-LRB- A -RRB- BBB open-fi eld locomotor scores .	16125
-LRB- A -RRB-	16125
BBB open-fi eld locomotor scores	16129
BBB	16129
open-fi eld locomotor scores	16133
Hindlimb gait	16163
fi rst	16181
1 week after SCI , i.e. before transplantation -LRB- Tx -RRB-	16197
1 week after SCI , i.e.	16197
1 week	16197
SCI	16210
transplantation -LRB- Tx -RRB-	16227
transplantation	16227
Tx	16244
weekly	16263
rats	16295
any signifi	16315
cant differences between one other	16327
cant differences	16327
one other	16352
a signifi cant difference	16367
7 weeks	16405
SCI	16419
all of the transplanted groups and the control group -LRB- ∗ P < 0.05 -RRB-	16431
all	16431
the transplanted groups and the control group -LRB- ∗ P < 0.05 -RRB-	16438
the transplanted groups	16438
the control group -LRB- ∗ P < 0.05 -RRB-	16466
the control group	16466
∗ P < 0.05	16485
∗ P	16485
< 0.05	16488
<	16488
0.05	16490
-LRB- B -RRB-	16497
The latency	16501
seconds	16517
the hindlimb in response	16538
the hindlimb	16538
response	16554
a heat stimulus	16566
the Plantar test	16598
rats	16629
their response	16643
the thermal stimulus	16661
a signifi cant difference compared to the control group	16683
a signifi cant difference	16683
the control group	16721
6 weeks after SCI in the OEG - and MSC-transplanted groups and from 7 weeks	16754
6 weeks	16754
SCI in the OEG - and MSC-transplanted groups	16768
SCI	16768
the OEG	16775
MSC-transplanted groups	16788
7 weeks	16821
SCI in the OEG/MSC-transplanted group -LRB- ∗ P < 0.05 -RRB-	16835
SCI	16835
the OEG/MSC-transplanted group -LRB- ∗ P < 0.05 -RRB-	16842
the OEG/MSC-transplanted group	16842
∗ P < 0.05	16874
∗ P	16874
< 0.05	16877
<	16877
0.05	16879
Tx	16886
the day of transplantation	16895
the day	16895
transplantation	16906
Figure 2 .	16924
Figure	16924
2	16931
Representative MEP	16934
transplanted and control rats 6 weeks after SCI -LRB- A -RRB-	16965
transplanted and control rats	16965
6 weeks	16995
SCI -LRB- A -RRB-	17009
SCI	17009
A	17014
The maximum amplitudes -LRB- μV -RRB- -LRB- B -RRB-	17018
The maximum amplitudes -LRB- μV -RRB-	17018
The maximum amplitudes	17018
μV	17042
B	17047
the latency -LRB- ms -RRB- -LRB- C -RRB- obtained from individual animals	17054
the latency -LRB- ms -RRB- -LRB- C -RRB-	17054
the latency -LRB- ms -RRB-	17054
the latency	17054
ms	17067
C	17072
individual animals	17089
a scatterplot	17121
1-week intervals following transplantation or saline injection -LRB- Tx -RRB-	17138
1-week intervals	17138
transplantation or saline injection -LRB- Tx -RRB-	17165
transplantation or saline injection	17165
Tx	17202
The linear regression lines	17207
solid lines	17248
Figure 3 .	17262
Figure	17262
3	17269
CFDA-SE-stained OEG -LRB- green -RRB- and SNARF-1-stained MSC -LRB- red -RRB-	17272
CFDA-SE-stained OEG -LRB- green -RRB-	17272
CFDA-SE-stained OEG	17272
SNARF-1-stained MSC -LRB- red -RRB-	17304
SNARF-1-stained MSC	17304
red	17325
the Methods	17335
a balloon-induced SCI 1 week after transplantation -LRB- A -RRB-	17351
a balloon-induced SCI 1 week	17351
transplantation -LRB- A -RRB-	17386
transplantation	17386
A	17403
MSC -LRB- B -RRB- and OEG -LRB- C -RRB- obtained from GFP transgenic rats	17407
MSC -LRB- B -RRB-	17407
MSC	17407
B	17412
OEG -LRB- C -RRB- obtained from GFP transgenic rats	17419
OEG -LRB- C -RRB-	17419
OEG	17419
C	17424
GFP transgenic rats	17441
brilliant green color	17468
the spinal cord 9 weeks	17493
the spinal cord	17493
9 weeks	17509
SCI	17523
MSC	17528
such long and thin processes as OEG	17545
such long and thin processes	17545
OEG	17577
OEG	17595
a conduit	17616
each other	17642
OEG expressing p75 -LRB- D -RRB-	17663
OEG	17663
p75 -LRB- D -RRB-	17678
p75	17678
D	17683
their long processes	17695
each other	17730
The balloon-compressed spinal cord	17742
copious vacuoles	17798
Corticospinal tract axons	17816
the control animals -LRB- E -RRB-	17873
the control animals	17873
E	17894
the lesioned spinal cords -LRB- arrows -RRB-	17914
the lesioned spinal cords	17914
arrows	17941
8 weeks	17949
OEG/MSC transplantation	17963
F	17988
Figure 4 .	17993
Figure	17993
4	18000
Cross-sectional areas -LRB- mm2 -RRB- of the white -LRB- A -RRB-	18003
Cross-sectional areas -LRB- mm2 -RRB-	18003
Cross-sectional areas	18003
mm2	18026
the white -LRB- A -RRB-	18034
gray -LRB- B -RRB- matter	18052
B	18058
1-mm increments	18079
the injury epicenter , which is shown as 0	18100
the injury epicenter	18100
0	18140
Numbers	18143
the distance	18160
the injury epicenter in millimeters	18178
the injury epicenter	18178
millimeters	18202
The spared areas	18215
the type of transplanted cell	18259
the type	18259
transplanted cell	18271
Figure 5 .	18291
Figure	18291
5	18298
The total volumes -LRB- mm3 -RRB- of the white and gray matter	18301
The total volumes -LRB- mm3 -RRB-	18301
The total volumes	18301
mm3	18320
the white and gray matter	18328
area measurements	18370
21-mm long segments of the lesioned spinal cord	18404
21-mm long segments	18404
the lesioned spinal cord	18427
The volume of the white matter	18453
The volume	18453
the white matter	18467
the transplanted groups	18498
the control group -LRB- A -RRB- -LRB- ∗ P < 0.05 , ∗ ∗ P < 0.01 -RRB-	18530
the control group -LRB- A -RRB-	18530
the control group	18530
A	18549
∗ P < 0.05 , ∗ ∗ P < 0.01	18553
∗ P	18553
< 0.05 , ∗ ∗ P < 0.01	18556
< 0.05 , ∗ ∗ P <	18556
<	18556
0.05	18558
∗ ∗ P	18564
0.01	18570
The gray matter	18577
the OEG/MSC - and MSC-transplanted rats	18612
the controls -LRB- B -RRB- -LRB- ∗ ∗ P < 0.01 -RRB-	18665
the controls -LRB- B -RRB-	18665
the controls	18665
B	18679
∗ P <	18684
∗ P	18684
<	18687
0.01	18689
The volumes -LRB- mm3 -RRB- of the white and gray matter	18696
The volumes -LRB- mm3 -RRB-	18696
The volumes	18696
mm3	18709
the white and gray matter	18717
the area	18763
2-mm cranial and caudal to the injury epicenter , where the cells were implanted	18780
2-mm cranial and caudal to the injury epicenter	18780
the injury	18807
the cells	18835
There	18861
no signifi cant difference in the white matter volume -LRB- C -RRB-	18871
no signifi cant difference	18871
the white matter volume -LRB- C -RRB-	18901
the white matter volume	18901
C	18926
the gray matter	18933
the injection sites -LRB- D -RRB- -LRB- ∗ ∗ P < 0.01 -RRB-	18986
the injection sites -LRB- D -RRB-	18986
the injection sites	18986
D	19007
∗ P <	19012
∗ P	19012
<	19015
0.01	19017
Functional outcome BBB	19025
Hindlimb locomotion	19054
SCI	19100
an open-fi eld BBB test	19110
The animals	19135
a BBB score of 0	19151
a BBB score	19151
0	19166
the induction of the balloon compression lesion	19186
the induction	19186
the balloon compression lesion	19203
Some of the three joints in the hindlimb	19235
Some	19235
the three joints in the hindlimb	19243
the three joints	19243
the hindlimb	19263
their ability to move during the fi rst post-surgical week	19294
the fi rst	19323
post-surgical week	19334
the animals	19358
their paws	19383
the ground	19397
The control animals	19409
BBB scores of 7.08	19438
BBB scores	19438
7.08	19452
± 0.24	19457
the end	19467
the experiment -LRB- 9 weeks after SCI , 8 weeks after transplantation -RRB-	19478
the experiment	19478
9 weeks after SCI , 8 weeks after transplantation	19494
9 weeks	19494
SCI , 8 weeks after transplantation	19508
SCI	19508
8 weeks after transplantation	19513
8 weeks	19513
transplantation	19527
their body weight	19564
their hind legs	19585
the fi rst	19609
week	19620
transplantation	19631
the transplanted animals	19648
a tendency to improve their BBB scores	19688
their BBB scores	19710
the transplanted groups	19734
the fastest recovery	19759
animals transplanted with OEG	19796
animals	19796
OEG	19822
These animals	19827
signifi	19848
cant improvement	19856
the controls as early as 4 weeks after SCI -LRB- P < 0.05 -RRB-	19887
the controls	19887
early as 4 weeks	19903
SCI	19926
P < 0.05	19931
P	19931
< 0.05	19933
<	19933
0.05	19935
their fi nal BBB score	19945
their fi	19945
nal BBB score	19954
9.30 ± 0.46	19972
9.30	19972
0.46	19979
Animals with OEG and MSC co-grafts	19985
Animals	19985
OEG and MSC co-grafts	19998
they	20033
six injections	20047
cant	20094
ment 6 weeks after SCI , with a fi nal BBB	20107
ment	20107
6 weeks	20112
SCI	20126
a fi	20136
nal BBB	20141
9.18 ± 0.44	20158
One week	20171
i.e. 7 weeks after SCI	20187
i.e.	20187
7 weeks after SCI	20192
7 weeks	20192
SCI	20206
similar motor improvement	20212
MSC-transplanted rats -LRB- fi nal BBB score of 8.94 ± 0.42 -RRB-	20254
MSC-transplanted rats	20254
fi nal BBB score of 8.94 ± 0.42	20277
fi	20277
nal BBB score of 8.94 ± 0.42	20280
nal BBB score	20280
8.94 ± 0.42	20297
Figure 1A	20311
All transplanted animals	20323
their gait	20358
some of them	20370
some	20370
them	20378
their body weight	20413
paw stepping , and two animals from the OEG	20446
paw stepping	20446
paw	20446
two animals from the OEG	20464
two animals	20464
the OEG	20481
MSC-transplanted groups	20494
co-ordination of the forelimbs and hindlimbs	20525
co-ordination	20525
the forelimbs and hindlimbs	20542
conclusion	20583
there	20594
no signifi	20605
cant differences	20616
any of the transplanted animal groups in terms of overall functional	20639
any	20639
the transplanted animal groups in terms of overall functional	20646
the transplanted animal groups	20646
terms of overall functional	20680
terms	20680
overall functional	20689
overall	20689
ment	20716
the end of the experiment -LRB- P < 0.05 -RRB-	20724
the end	20724
the experiment -LRB- P < 0.05 -RRB-	20735
the experiment	20735
P < 0.05	20751
P	20751
< 0.05	20753
<	20753
0.05	20755
Plantar test The withdrawal latency	20762
Plantar test	20762
The withdrawal latency	20775
the hindpaws in response to a thermal stimulus	20801
the hindpaws	20801
response to a thermal stimulus	20817
response	20817
a thermal stimulus	20829
a week	20866
the fi rst post-operative week -LRB- before trans plantation -RRB-	20881
the fi rst post-operative week	20881
trans plantation	20920
the average latency of hindpaw withdrawal	20939
the average latency	20939
hindpaw withdrawal	20962
three repeated measurements	20998
5-min intervals	21029
7.18 ± 0.30 , 6.75 ± 0.24 , 7.51 ± 0.27 and 7.18 ± 0.44 s , in OEG/MSC - , OEG	21050
7.18 ± 0.30 , 6.75 ± 0.24 , 7.51 ± 0.27 and 7.18 ± 0.44 s , in OEG/MSC - ,	21050
7.18 ± 0.30	21050
7.18	21050
0.30	21057
6.75 ± 0.24 , 7.51 ± 0.27 and 7.18 ± 0.44 s	21063
6.75 ± 0.24 , 7.51 ± 0.27	21063
6.75 ± 0.24	21063
6.75	21063
0.24	21070
7.51 ± 0.27	21076
7.51	21076
0.27	21083
7.18 ± 0.44 s	21092
7.18	21092
0.44 s	21099
OEG/MSC	21110
MSC-transplanted rats and control rats , respectively	21129
MSC-transplanted rats and control rats	21129
The latency of each group	21183
The latency	21183
each group	21198
the second week following lesion induction	21235
the second week	21235
lesion induction	21261
The control group	21279
the transplanted groups	21338
their withdrawal latency	21372
each subsequent week	21404
Signifi cant differences from the control rats -LRB- P < 0.05 -RRB-	21426
Signifi cant differences from the control rats	21426
Signifi cant differences	21426
the control rats	21456
P < 0.05	21474
P	21474
< 0.05	21476
<	21476
0.05	21478
the transplanted rats during the sixth post-surgical week	21505
the transplanted rats	21505
the sixth post-surgical week	21534
The fi nal values determined	21564
nal values	21571
9 weeks	21593
SCI were 5.83 ± 0.25 , 5.69 ± 0.21 and 5.42 ± 0.22 s in OEG / MSC	21607
SCI	21607
5.83 ± 0.25 , 5.69 ± 0.21 and 5.42 ± 0.22 s in OEG / MSC	21616
5.83 ± 0.25 , 5.69 ± 0.21 and 5.42 ± 0.22 s in OEG /	21616
5.83 ± 0.25	21616
5.83	21616
0.25	21623
5.69 ± 0.21	21629
5.69	21629
0.21	21636
5.42 ± 0.22 s in OEG /	21645
5.42 ± 0.22 s	21645
5.42	21645
0.22 s	21652
MSC-transplanted rats , respectively -LRB- Figure 1B -RRB- ; these values	21682
MSC-transplanted rats , respectively -LRB- Figure 1B -RRB-	21682
MSC-transplanted rats , respectively	21682
MSC-transplanted rats	21682
Figure 1B	21719
these values	21731
signifi	21749
P < 0.05	21775
P	21775
< 0.05	21777
<	21777
0.05	21779
those of the control group -LRB- 6.72 ± 0.12 s -RRB-	21790
those	21790
the control group -LRB- 6.72 ± 0.12 s -RRB-	21799
the control group	21799
6.72 ± 0.12 s	21818
6.72 ± 0.12	21818
6.72	21818
0.12	21825
s	21830
Hyperalgesia	21834
OEG and/or MSC transplantation	21872
OEG	21872
MSC transplantation	21883
Electrophysiologic evaluation MEP	21904
the induction of the balloon compression lesion	21969
the induction	21969
the balloon compression lesion	21986
The peak amplitude of MEP	22018
The peak amplitude	22018
MEP	22040
7.19 ± 0.41 mV	22048
7.19	22048
0.41 mV	22055
average in intact rats	22066
average	22066
intact rats	22077
the balloon	22095
saline	22126
a bursting discharge	22134
MEP	22169
1 min	22193
balloon infl ation	22205
The MEP	22225
amplitude	22258
between 5 and 15 μV	22271
the 5-min compression procedure	22298
stronger electric stimuli	22335
their amplitude	22386
the surgery	22420
MEP	22433
2 weeks to 6 weeks	22463
2 weeks	22463
6 weeks	22474
SCI	22488
Figure 2A	22493
representative MEP	22509
individual animals	22540
each group	22564
Figure 2B	22582
the maximum amplitudes recorded in all animals	22598
the maximum amplitudes	22598
all animals	22633
the type of transplanted cells	22669
the type	22669
transplanted cells	22681
OEG/MSC , OEG , MSC and control	22701
Linear regression	22732
the signifi cance of the increase in MEP amplitude	22770
the signifi cance	22770
the increase in MEP amplitude	22791
the increase	22791
MEP amplitude	22807
time	22826
There	22832
no signifi cant impact	22842
the slope	22868
the linear regression line	22881
the control rats -LRB- R2 = 0.004 , P = 0.278 -RRB-	22911
the control rats	22911
R2 = 0.004 , P = 0.278	22929
R2	22929
= 0.004 , P = 0.278	22932
= 0.004 , P	22932
0.004	22934
0.278	22945
The MEP of the control animals	22953
The MEP	22953
the control animals	22964
any improvement in amplitude	22997
any improvement	22997
amplitude	23016
between 15 and 40 μV	23041
6 weeks	23062
contrast	23090
the transplanted groups	23100
more	23131
improvement than the control group	23136
improvement	23136
the control group	23153
A signifi cant difference	23172
5 and 6 weeks after SCI	23208
5 and 6 weeks	23208
SCI	23228
2 weeks	23246
SCI -LRB- P < 0.05 -RRB- in the OEG/MSC-transplanted group	23260
SCI -LRB- P < 0.05 -RRB-	23260
SCI	23260
P < 0.05	23265
P	23265
< 0.05	23267
<	23267
0.05	23269
the OEG/MSC-transplanted group	23278
2 weeks	23321
6 weeks	23333
SCI -LRB- P < 0.01 -RRB- in the OEG-transplanted group	23347
SCI -LRB- P < 0.01 -RRB-	23347
SCI	23347
P < 0.01	23352
P	23352
< 0.01	23354
<	23354
0.01	23356
the OEG-transplanted group	23365
Linear regression analysis	23393
the weekly increases	23432
amplitude	23456
statistically signifi cant in the OEG/MSC - -LRB- R2 = 0.122 , P = 0.002 -RRB- ,	23471
statistically signifi	23471
cant	23493
the OEG/MSC -	23501
the OEG/MSC	23501
R2 = 0.122 , P	23515
R2	23515
0.122 , P	23520
0.122	23520
P	23527
0.002	23531
R2 = 0.132 , P = 0.0002	23545
R2	23545
= 0.132 , P = 0.0002	23548
= 0.132 , P	23548
0.132	23550
0.0002	23561
MSC-transplanted groups -LRB- R2 = 0.037 , P = 0.038 -RRB-	23573
MSC-transplanted groups	23573
R2 = 0.037 , P = 0.038	23598
R2	23598
= 0.037 , P = 0.038	23601
= 0.037 , P	23601
0.037	23603
0.038	23614
The duration of the response and the latency to onset of the response	23622
The duration	23622
the response and the latency to onset of the response	23638
the response	23638
the latency to onset of the response	23655
the latency	23655
onset of the response	23670
onset	23670
the response	23679
5.55 ± 1.37 ms and 4.81 ± 0.67 ms	23697
5.55 ± 1.37 ms	23697
5.55	23697
1.37 ms	23704
4.81 ± 0.67 ms	23716
4.81	23716
0.67 ms	23723
the intact animals	23734
The duration of MEP	23768
The duration	23768
MEP	23784
1 ms	23804
SCI	23815
The response duration of MEP	23820
The response duration	23820
MEP	23845
the OEG/MSC - and MSCtransplanted groups	23870
the OEG/MSC	23870
MSCtransplanted groups	23887
week	23935
week in the OEG-transplanted and control groups	23943
week	23943
the OEG-transplanted and control groups	23951
A difference	23992
1 week	24018
transplantation -LRB- 2 weeks after SCI -RRB-	24031
transplantation	24031
2 weeks after SCI	24048
2 weeks	24048
SCI	24062
OEG/MSC - and MSC-transplanted rats	24075
the control rats -LRB- P 0.05 ; data not shown -RRB-	24114
the control rats	24114
P 0.05 ; data not shown	24132
P 0.05	24132
data not shown	24142
data	24142
The latency	24159
normal values	24209
the experiment	24234
Linear regression analysis	24250
a tendency towards decreased latency in the transplanted groups	24286
a tendency	24286
decreased latency in the transplanted groups	24305
decreased latency	24305
the transplanted groups	24326
the slope of the linear regression line	24366
the slope	24366
the linear regression line	24379
statistically signifi cant	24410
the OEG/MSC-transplanted group -LRB- R2 0.095 , P 0.044 -RRB-	24440
the OEG/MSC-transplanted group	24440
R2 0.095	24472
P 0.044	24484
contrast	24499
there	24509
no such tendency observed in the control group -LRB- Figure 2C -RRB-	24519
no such tendency	24519
the control group -LRB- Figure 2C -RRB-	24548
the control group	24548
Figure 2C	24567
Histology Cell survival .	24579
Histology Cell	24579
survival	24594
cell survival	24615
SCI	24632
we	24637
longitudinal cryosections of the ballooncompressed spinal cord	24649
longitudinal cryosections	24649
the ballooncompressed spinal cord	24678
The green fl uorescence expressed by CFDA-SE-labeled OEG	24713
The green fl uorescence	24713
CFDA-SE-labeled OEG	24750
a fl uorescent microscope	24788
8 weeks of observation	24825
8 weeks	24825
observation	24836
transplantation	24854
SNARF-1 - or CFDA-SE-labeled MSC	24880
SNARF-1	24880
CFDA-SE-labeled MSC	24892
only 4 or 5 weeks	24929
SCI -LRB- Figure 3A -RRB-	24953
SCI	24953
Figure 3A	24958
MSC	24992
It	25011
the concentration of the	25033
the concentration	25033
the	25054
longer observation	25083
more reliable tracking of the cells in vivo	25124
more reliable tracking	25124
the cells in vivo	25150
the cells	25150
vivo	25163
OEG and MSC obtained from GFP transgenic rats	25169
OEG and MSC	25169
GFP transgenic rats	25195
long-term tracking	25229
Transplants of both types of cells	25249
Transplants	25249
both types of cells	25264
both types	25264
cells	25278
every week	25310
the same way	25324
MSC -LRB- Figure 3B -RRB- and OEG -LRB- Figure 3C -RRB-	25348
MSC -LRB- Figure 3B -RRB-	25348
MSC	25348
Figure 3B	25353
OEG -LRB- Figure 3C -RRB-	25368
OEG	25368
Figure 3C	25373
GFP rats	25389
their vivid green color	25424
the spinal cord for 8 weeks	25451
the spinal cord	25451
8 weeks	25471
None of the studied cell types	25480
None	25480
the studied cell types	25488
any extensive migration	25518
the spinal cord tissue	25549
they	25576
the injection sites	25618
the injection pressure	25667
MSC	25691
the injection sites	25709
transplantation	25735
OEG	25758
their long processes	25771
close contact	25808
one another	25827
It	25840
OEG	25858
conduits	25869
they	25882
the lamina propria	25893
the olfactory axons -LRB- Figure 3C -RRB-	25942
the olfactory axons	25942
Figure 3C	25963
Such dynamic behavior of OEG	25975
Such dynamic behavior	25975
OEG	26000
OEG	26032
each other	26055
their long processes -LRB- Figure 3D -RRB-	26078
their long processes	26078
Figure 3D	26100
the end of the experiments	26115
the end	26115
the experiments	26126
the number of surviving cells	26143
the number	26143
surviving cells	26157
There	26186
great differences between individual animals even in the same group	26197
great differences	26197
individual animals even in the same group	26223
individual animals	26223
the same group	26250
The percentage of surviving MSC and OEG was 0.41	26266
The percentage	26266
MSC and OEG	26294
0.41	26310
0.96 % and 0.34	26315
0.96 %	26315
0.34	26325
1.72 % , respectively	26330
1.72 %	26330
Similar cell survival rates	26351
the co-transplanted group	26396
Nestin and βIII-tubulin staining	26423
any positive cells	26471
the transplanted OEG or MSC 8 weeks	26496
the transplanted OEG	26496
MSC 8 weeks	26520
MSC	26520
8 weeks	26524
transplantation	26538
Morphometric evaluation The area of the spinal cord	26555
Morphometric evaluation The area	26555
the spinal cord	26591
serial cross-sections	26627
1-cm cranial and 1-cm caudal	26649
the injury epicenter , which was identifi	26683
the injury epicenter	26683
the thinnest part of the thoracic spinal cord	26730
the thinnest part	26730
the thoracic spinal cord	26751
The crosssectional areas -LRB- mm2 -RRB- of the white and gray matter	26777
The crosssectional areas -LRB- mm2 -RRB-	26777
The crosssectional areas	26777
mm2	26803
the white and gray matter	26811
1-mm increments	26853
the injury epicenter -LRB- Figure 4A , B -RRB-	26874
the injury epicenter	26874
Figure 4A , B	26896
Figure 4A	26896
B	26907
The cross-sectional area of the spared white and gray matter	26911
The cross-sectional area	26911
the spared white and gray matter	26939
any 1-mm distant sectional point in the control group	26994
any 1-mm distant sectional point	26994
the control group	27030
the transplanted groups	27056
some of differences in area	27085
some	27085
differences in area	27093
differences	27093
area	27108
statistical signifi cance	27121
the total volume of the white and gray matter -LRB- mm3 -RRB-	27153
the total volume	27153
the white and gray matter -LRB- mm3 -RRB-	27173
the white and gray matter	27173
mm3	27200
area measurements	27225
21-mm long segments	27259
a larger volume of spared white matter	27280
a larger volume	27280
spared white matter	27299
rats	27335
type	27359
cell -LRB- 36.9 ± 1.9 mm3 , 38.8 ± 1.2 mm3 and 38.9 ± 0.8 mm3 in the OEG /	27367
cell -LRB- 36.9 ± 1.9 mm3	27367
cell	27367
36.9 ± 1.9 mm3	27373
36.9 ±	27373
1.9 mm3	27380
±	27394
1.2 mm3	27396
± 0.8 mm3 in the OEG	27413
± 0.8 mm3	27413
the OEG	27426
and MSC-transplanted rats , respectively -RRB-	27446
MSC-transplanted rats , respectively -RRB-	27450
MSC-transplanted rats	27450
30.7 ±	27501
0.9 mm3 in the control animals -LRB- P < 0.05 ; Figure 5A -RRB-	27508
0.9 mm3	27508
the control animals -LRB- P < 0.05 ; Figure 5A -RRB-	27519
the control animals	27519
P < 0.05 ; Figure 5A	27540
P	27540
< 0.05 ; Figure 5A	27542
< 0.05	27542
<	27542
0.05	27544
Figure 5A	27550
Figure	27550
5A	27557
The volume of gray matter calculated from 21-mm long segments	27562
The volume	27562
gray matter calculated from 21-mm long segments	27576
gray matter	27576
21-mm long segments	27604
OEG/MSC and MSC transplants	27638
terms of gray matter sparing -LRB- Figure 5B ; P < 0.01 -RRB-	27689
terms	27689
gray matter sparing -LRB- Figure 5B ; P < 0.01 -RRB-	27698
gray matter sparing	27698
Figure 5B ; P < 0.01	27719
Figure 5B	27719
P < 0.01	27730
P <	27730
P	27730
0.01	27734
the volume of the spared white and gray matter	27746
the volume	27746
the spared white and gray matter	27760
the cranial half and caudal half segments	27814
the cranial half	27814
caudal half segments	27835
the injury epicenter	27861
a signifi cant difference in the volume of the white matter	27883
a signifi cant difference	27883
the volume of the white matter	27912
the volume	27912
the white matter	27926
the caudal segments	27956
OEG-transplanted rats and control rats -LRB- P < 0.05 -RRB-	27984
OEG-transplanted rats and control rats	27984
P < 0.05	28024
P	28024
< 0.05	28026
<	28026
0.05	28028
The white matter	28035
the thoracic segments	28073
the injury epicenter in OEG-transplanted rats , while in OEG / MSC	28105
the injury epicenter	28105
OEG-transplanted rats	28129
OEG	28161
MSC-transplanted rats	28175
the white matter	28197
the cranial and caudal segments	28239
the other hand	28275
the gray matter	28291
cranial segments in both OEG/MSCand MSC-transplanted animals	28326
cranial segments in both OEG/MSCand	28326
cranial segments	28326
both OEG/MSCand	28346
P < 0.05	28388
P	28388
< 0.05	28390
<	28390
0.05	28392
The volume	28399
the gray matter	28413
the area between 2-mm cranial and 2-mm caudal	28444
the area	28444
2-mm cranial and 2-mm caudal	28461
the injury epicenter	28493
the cells	28521
the gray matter	28562
the injection sites -LRB- Figure 5C , D -RRB-	28608
the injection sites	28608
Figure 5C , D	28629
Figure 5C	28629
D	28640
The volume of the gray matter in the transplanted animals	28644
The volume	28644
the gray matter in the transplanted animals	28658
the gray matter	28658
the transplanted animals	28677
signifi cantly different from that in the control animals -LRB- P < 0.01 -RRB-	28706
signifi cantly different from that in the control animals	28706
that in the control	28736
that	28736
the control	28744
P < 0.01	28765
P	28765
< 0.01	28767
<	28767
0.01	28769
Anterograde tracing	28776
Anterograde	28776
a larger volume of the white matter	28816
a larger volume	28816
the white matter	28835
the corticospinal axons	28864
the spared white matter -LRB- Figure 3F -RRB-	28909
the spared white matter	28909
Figure 3F	28934
Axons	28946
the injury epicenter in the control rats -LRB- Figure 3E -RRB-	28978
the injury epicenter	28978
the control rats -LRB- Figure 3E -RRB-	29002
the control rats	29002
Figure 3E	29020
Discussion The subacute phase , up to 3 -- 4 weeks after SCI ,	29033
Discussion The subacute phase , up to 3	29033
Discussion	29033
The subacute phase	29044
3	29070
4 weeks after SCI	29072
4 weeks	29072
SCI	29086
the therapeutic window for cell therapy	29094
the therapeutic window	29094
cell therapy	29121
humans	29137
animal models -LRB- 30 -RRB-	29158
animal models	29158
30	29173
Cell survival	29178
the cells	29207
the subacute phase	29237
the acute phase of SCI -LRB- 31 -RRB-	29271
the acute phase	29271
SCI -LRB- 31 -RRB-	29290
SCI	29290
31	29295
Cells	29300
SCI	29337
a hostile environment characterized by infl ammation	29351
a hostile environment	29351
infl ammation	29390
the up-regulation	29405
pro-infl ammatory cytokines	29426
tumor necrosis factor-alpha , interleukin-1-beta	29455
tumor necrosis factor-alpha	29455
interleukin-1-beta	29484
ischemia , toxic substances such as free radicals	29505
ischemia	29505
toxic substances such as free radicals	29515
toxic substances	29515
free radicals	29540
the loss of ionic homeostasis -LRB- 32 -RRB-	29558
the loss	29558
ionic homeostasis -LRB- 32 -RRB-	29570
ionic homeostasis	29570
32	29589
the subacute phase	29597
phagocytosis	29617
a supportive environment	29670
neural sprouting by removing cell debris	29699
neural	29699
cell debris	29728
inhibitory components	29751
axonal growth such as CSPG and myelin-associated glycoprotein -LRB- 33 -RRB-	29777
axonal growth	29777
CSPG and myelin-associated glycoprotein -LRB- 33 -RRB-	29799
CSPG	29799
myelin-associated glycoprotein -LRB- 33 -RRB-	29808
myelin-associated glycoprotein	29808
33	29840
CSPG production	29850
SCI	29895
spontaneous recovery	29900
CSPG	29935
a benefi cial effect on the injured spinal cord in the acute phase	29955
a benefi cial effect	29955
the injured spinal cord in the acute phase	29979
the injured spinal cord	29979
the acute phase	30006
microglia and macrophages -LRB- 34 -RRB-	30036
microglia and macrophages	30036
34	30063
the inhibitory regulation of microglial activity	30077
the inhibitory regulation	30077
microglial activity	30106
the later phase of SCI	30141
the later phase	30141
SCI	30160
neural cell damage proceeds as a result of cytokines	30172
neural cell damage proceeds	30172
a result of cytokines	30203
a result	30203
cytokines	30215
free radicals released from proliferating microglia -LRB- 35 -RRB-	30229
free radicals	30229
proliferating microglia -LRB- 35 -RRB-	30257
proliferating microglia	30257
35	30282
OEG and MSC	30292
7 days	30325
SCI in our study	30338
SCI	30338
our study	30345
agreement with previous studies -LRB- 19 -RRB-	30359
agreement	30359
previous studies -LRB- 19 -RRB-	30374
previous studies	30374
19	30392
our results	30397
hindlimb locomotion	30419
OEG - and MSC-transplanted rats	30451
their co-transplantation	30492
additive and synergistic functional improvements	30539
OEG and MSC	30589
a propensity to migrate towards an injury site -LRB- 36 -- 38 -RRB-	30616
an injury site -LRB- 36 -- 38 -RRB-	30648
an injury site	30648
36 -- 38	30664
36	30664
38	30667
The GFP OEG and MSC transplants	30672
The GFP OEG	30672
MSC transplants	30688
the injection sites	30739
our experiments	30763
OEG and MSC	30780
the lesions	30813
they	30829
any considerable distance	30860
the other hand	30890
their poor migration	30906
one of the features of OEG obtained from the lamina propria -LRB- 39 -RRB-	30936
one	30936
the features of OEG obtained from the lamina propria -LRB- 39 -RRB-	30943
the features	30943
OEG obtained from the lamina propria -LRB- 39 -RRB-	30959
OEG	30959
the lamina propria -LRB- 39 -RRB-	30977
the lamina propria	30977
39	30997
Su et al. -LRB- 40 -RRB-	31002
Su et al.	31002
40	31013
post-injury upregulation of Nogo-A on oligodendrocytes	31032
post-injury upregulation	31032
Nogo-A on oligodendrocytes	31060
Nogo-A	31060
oligodendrocytes	31070
the adhesion of OEG via activation of Rho-A	31096
the adhesion	31096
OEG via activation of Rho-A	31112
OEG	31112
activation of Rho-A	31120
activation	31120
Rho-A	31134
their migration	31152
The increased activation of Rho after SCI -LRB- 41,42 -RRB-	31169
The increased activation of Rho after SCI	31169
The increased activation	31169
Rho	31197
SCI	31207
41,42	31212
the formation of MSC focal adhesions -LRB- 43,44 -RRB-	31232
the formation	31232
MSC focal adhesions -LRB- 43,44 -RRB-	31249
MSC focal adhesions	31249
43,44	31270
Poor cell migration	31278
the concerted actions	31319
OEG and MSC	31344
separate injections in our experiments	31381
separate injections	31381
our experiments	31404
Pre-treatment with a Rho antagonist or a Rho kinase inhibitor	31421
Pre-treatment	31421
a Rho antagonist or a Rho kinase inhibitor	31440
a Rho antagonist	31440
a Rho kinase inhibitor	31460
the co-transplantation of OEG and MSC	31508
the co-transplantation	31508
OEG and MSC	31534
cell migration	31560
axonal growth	31594
apoptosis	31620
the injured spinal cord -LRB- 40,45 -RRB-	31633
the injured spinal cord	31633
40,45	31658
SCI	31675
cell therapy	31680
a hostile niche	31715
neuronal sparing and regeneration	31735
the prevention of scar formation , inhibitory factors and demyelination	31780
the prevention	31780
scar formation , inhibitory factors and demyelination	31798
scar formation	31798
inhibitory factors	31814
demyelination	31837
new neural circuits	31869
the injured sites	31899
SCI	31924
the severed axons	31929
collaterals into the gray matter	31963
collaterals	31963
the gray matter	31980
46 -- 48	31997
46	31997
48	32000
new circuits	32008
propriospinal neurons in the incompletely damaged spinal cord -LRB- 49,50 -RRB-	32037
propriospinal neurons	32037
the incompletely damaged spinal cord -LRB- 49,50 -RRB-	32062
the incompletely damaged spinal cord	32062
49,50	32100
Functional recovery	32108
this newly established route	32154
The MEP	32184
a week	32206
very variable amplitudes	32220
each group and even	32248
the same animal	32271
The positions of the electrode for recording	32288
The positions	32288
the electrode for recording	32305
the electrode	32305
recording	32323
the same for every measurement	32350
the same	32350
every measurement	32363
permanent implantation	32393
electrodes into the muscle -LRB- 51 -RRB- or spinal cord -LRB- 52 -RRB-	32419
electrodes	32419
the muscle -LRB- 51 -RRB- or spinal cord -LRB- 52 -RRB-	32435
the muscle	32435
51	32447
spinal cord	32454
52	32467
periodic recordings	32496
a long-term experiment	32523
they	32549
the animal 's locomotion and behavior	32568
the animal 's	32568
the MEP	32618
variable amplitudes	32630
microvolt-levels	32670
the trend	32688
their increasing amplitude	32701
a 1-month observation period	32745
statistically signifi cant in the transplanted groups	32779
statistically signifi cant	32779
the transplanted groups	32809
The control group	32834
any improvement in amplitude	32865
any improvement	32865
amplitude	32884
the transplanted groups	32899
their amplitude	32932
week	32948
week	32956
the OEG-transplanted group	32977
the greatest improvement among the transplanted groups	33011
the greatest improvement	33011
the transplanted groups	33042
The latency of MEP	33067
The latency	33067
MEP	33082
normal values	33124
incomplete SCI	33144
another study	33189
53	33204
neural circuits	33217
the incompletely damaged spinal cord	33257
a tendency towards shortened -LRB- improved -RRB- latency	33304
a tendency towards shortened -LRB- improved -RRB-	33304
a tendency	33304
shortened -LRB- improved -RRB-	33323
latency	33344
the transplanted groups	33373
Our results	33398
the spared and recovered circuits for locomotor activity	33423
the	33423
circuits for locomotor activity	33448
circuits	33448
locomotor activity	33461
high MEP amplitudes	33506
such weak signal improvement	33536
weight-supported stepping	33581
weight-supported	33581
co-ordination between the forelimbs and hindlimbs in some cases	33611
co-ordination	33611
the forelimbs and hindlimbs in some cases	33633
the forelimbs and hindlimbs	33633
some cases	33664
This	33676
histologic fi ndings of residual axons in the spinal cord	33698
histologic fi ndings	33698
residual axons in the spinal cord	33722
residual axons	33722
the spinal cord	33740
Fehlings and Tator -LRB- 54 -RRB-	33757
Fehlings and Tator	33757
Fehlings	33757
Tator	33770
54	33777
12 % of axons	33792
12 %	33792
axons	33799
the spinal cord	33817
SCI and sustained neurologic function	33839
SCI	33839
sustained neurologic function	33847
rats	33880
The initial mechanical trauma and subsequent infl ammatory processes	33886
The initial mechanical trauma	33886
subsequent infl ammatory processes	33920
the apoptosis	33963
oligodendrocytes , which results in demyelination -LRB- 55,56 -RRB-	33980
oligodendrocytes	33980
demyelination -LRB- 55,56 -RRB-	34015
demyelination	34015
55,56	34030
OEG remyelinate	34038
axons	34067
SCI	34079
themselves -LRB- 57 -RRB-	34093
themselves	34093
57	34105
the entry of host Schwann cells	34128
the entry	34128
host Schwann cells	34141
the injured spinal cord -LRB- 58 -RRB-	34165
the injured spinal cord	34165
58	34190
The tendency towards shorter MEP latencies	34195
The tendency	34195
shorter MEP latencies	34216
signifi cant only in the co-transplanted group	34242
signifi cant	34242
the co-transplanted group	34263
The remyelination process	34290
this functional improvement	34344
Sensory afferent inputs	34373
an important role in more sophisticated locomotion -LRB- 59 -RRB-	34402
an important role	34402
more sophisticated locomotion -LRB- 59 -RRB-	34423
more sophisticated locomotion	34423
59	34454
None of the transplanted rats	34459
None	34459
the transplanted rats	34467
a BBB score	34498
15 , which requires parallel paw position during locomotion	34522
15	34522
parallel paw position	34541
locomotion	34570
The animals	34582
their paw position	34612
sensory information	34647
the paw	34672
the fl oor	34712
Our results	34724
the same clear improvement	34749
the Plantar test	34779
a previous study where MSC were implanted intravenously -LRB- 19 -RRB-	34815
a previous study	34815
MSC	34838
19	34872
intraspinal injection	34885
additional damage	34917
the dorsal columns	34938
the results from the Plantar test	34958
the results	34958
the Plantar test	34975
the present study	35018
our previous MSC study	35042
the transplantation of both types of cells	35075
the transplantation	35075
both types of cells	35098
both types	35098
cells	35112
similar results	35125
their mechanisms of action	35142
their mechanisms	35142
action	35162
the damaged spinal cord	35196
It	35221
intravenous injection	35244
MSC 7 days after SCI improves locomotor activity and signifi cantly	35269
MSC	35269
7 days	35273
SCI	35286
locomotor activity and signifi	35299
white matter	35354
the lesion area	35370
19	35387
no sparing of gray matter	35401
no sparing	35401
gray matter	35415
MSC	35441
immunomodulatory effects -LRB- 60 -RRB-	35463
immunomodulatory effects	35463
60	35489
their systemic injection	35505
uence	35539
the levels of pro- and anti-infl ammatory cytokines	35545
the levels	35545
pro- and anti-infl ammatory cytokines	35559
this	35602
a trophic effect on functional recovery	35623
a trophic effect	35623
functional recovery	35643
the lesion	35670
7 days	35707
SCI	35720
the MSC	35728
a neuroprotective agent	35747
The slow improvement observed in the Plantar test	35772
The slow improvement	35772
the Plantar test	35805
these different routes of cell injection : intraspinal versus intravenous	35852
these different routes of cell injection	35852
these different routes	35852
cell injection	35878
intraspinal versus intravenous	35894
intraspinal	35894
intravenous	35913
Cell counts	35926
the poor survival of OEG and MSC	35945
the poor survival	35945
OEG and MSC	35966
the lesioned area	35993
The direct injection of each cell type	36012
The direct injection	36012
each cell type	36036
the gray matter	36058
our study	36077
the injury epicenter	36092
a habitable environment for transplanted cells -LRB- 31 -RRB-	36120
a habitable environment	36120
transplanted cells -LRB- 31 -RRB-	36148
transplanted cells	36148
31	36168
Subarachnoid injection	36173
an alternate and promising route for cell administration	36199
an alternate and promising route	36199
cell administration	36236
additional damage	36274
the spinal cord	36295
more effi cient cell delivery	36322
the spinal cord -LRB- 61,62 -RRB-	36355
the spinal cord	36355
61,62	36372
further study	36384
the environment in the cerebrospinal fl uid -LRB- CSF -RRB-	36423
the environment	36423
the cerebrospinal fl uid -LRB- CSF -RRB-	36442
the cerebrospinal fl uid	36442
CSF	36468
transplanted cells	36477
MSC	36497
the fourth ventricle	36515
the subarachnoid space in the spinal cord	36569
the subarachnoid space	36569
the spinal cord	36595
the CSF	36619
behavioral recovery	36640
SCI	36666
these MSC	36675
3 weeks after injection	36704
3 weeks	36704
injection	36718
an immunosuppressant -LRB- 63 -RRB-	36740
an immunosuppressant	36740
63	36762
Repeated subarachnoid administration of cells	36767
Repeated subarachnoid administration	36767
cells	36807
the long-term effects of the transplanted cells on the damaged host tissue	36845
the long-term effects	36845
the transplanted cells on the damaged host tissue	36870
the transplanted cells	36870
the damaged host tissue	36896
Vanicky et al. -LRB- 21 -RRB-	36921
Vanicky et al.	36921
Vanicky	36921
et al.	36929
21	36937
balloon compression	36953
a complete loss	36982
gray matter , a partial loss of white matter and copious vacuoles	37001
gray matter	37001
a partial loss of white matter	37014
a partial loss	37014
white matter	37032
copious vacuoles	37049
Our morphometric analysis	37067
the cross-sectional area of the gray matter around the injury epicenter	37112
the cross-sectional area	37112
the gray matter around the injury epicenter	37140
the gray matter	37140
the injury epicenter	37163
0 -- 0.013 mm2 in the control animals	37188
0	37188
0.013 mm2 in the control animals	37190
0.013 mm2	37190
the control animals	37203
the gray matter	37233
the treated animals	37275
The white matter	37296
the lesioned spinal cord with the OEG/MSC and MSC transplants	37335
the lesioned spinal cord	37335
the OEG/MSC and MSC transplants	37365
OEG transplants	37404
the white matter	37430
the caudal segments	37450
the cranial segments	37483
The gray matter	37505
a greater extent	37535
the MSC	37555
and MSC-transplanted rats , especially in the spinal cord cranial	37569
MSC-transplanted rats	37573
the spinal cord	37610
the injury epicenter	37637
other words	37662
the gray matter sparing	37675
the gray matter	37675
the aid of MSC transplantation	37713
the aid	37713
MSC transplantation	37724
the white matter sparing resulting from OEG transplantation	37751
the white matter	37751
OEG transplantation	37791
spinal tract axons	37832
degeneration	37856
the early stages	37876
SCI	37896
turn	37910
the faster recovery of simple locomotor function	37929
the faster recovery	37929
simple locomotor function	37952
the volume between 2-mm cranial and 2-mm caudal	38000
the volume	38000
2-mm cranial and 2-mm caudal	38019
the injury epicenter , where the OEG and/or MSC were mainly implanted	38051
the injury epicenter	38051
the OEG and/or MSC	38079
the OEG	38079
MSC	38094
there	38121
no statistical difference	38131
the volume of the white matter between the transplanted and control groups	38160
the volume	38160
the white matter between the transplanted and control groups	38174
the white matter between the transplanted	38174
the white matter	38174
the transplanted	38199
control groups	38220
contrast	38239
a signifi cant difference	38249
the volume of the gray matter	38288
the volume	38288
the gray matter	38302
OEG and MSC	38319
the ability to spare the white and gray matter in the injured spinal cord	38335
the white and gray matter in the injured spinal cord	38356
the white and gray matter	38356
the injured spinal cord	38385
the gray matter	38425
the damaged area of the spinal cord	38467
the damaged area	38467
the spinal cord	38487
the transplants	38509
The gray matter	38549
metabolic damage than white matter	38588
metabolic damage	38588
white matter	38610
Balloon compression	38624
ischemic damage	38653
the spinal cord	38672
metabolic failure in the gray matter	38701
metabolic failure	38701
the gray matter	38722
We	38739
the transplants	38754
the gray matter	38777
such damage	38798
OEG and/or MSC treatment	38819
OEG	38819
MSC treatment	38830
the gray matter	38845
the white matter	38883
OEG and MSC	38919
more descending and ascending axons by sparing the white matter	38948
more	38948
axons	38978
the white matter	38995
they	39024
lost connections	39075
collaterals	39103
the spared axons	39120
the gray matter , which was also spared by the transplants	39140
the gray matter	39140
the transplants	39182
the gray matter	39202
interneurons	39219
neural connections	39261
the PNS and CNS	39285
OEG and/or MSC	39305
OEG	39305
MSC	39316
the animals	39340
the ability to support their body weight on their hind legs	39365
their body weight	39388
their hind legs	39409
we	39435
any unambiguous relationship	39454
the volume of the spared spinal cord tissue and behavioral improvement	39491
the volume	39491
the spared spinal cord tissue and behavioral improvement	39505
the spared spinal cord tissue	39505
behavioral improvement	39539
Functional recovery	39563
the viewpoint of synaptic reconstruction	39607
the viewpoint	39607
synaptic reconstruction	39624
the white and gray matter sparing induced by transplantation	39653
the white and gray matter	39653
transplantation	39698
the feasibility of this reconstruction	39724
the feasibility	39724
this reconstruction	39743
MSC	39773
mesodermal and non-mesodermal lineages -LRB- 64 -RRB-	39821
mesodermal and non-mesodermal lineages	39821
64	39861
they	39866
the mesodermal lineage	39903
Their potential to differentiate into neuronal cells	39927
Their potential	39927
neuronal cells	39965
controversial -LRB- 65,66 -RRB-	40003
controversial	40003
65,66	40018
our experiment	40029
nestin-positive and βIII-tubulin-positive transplanted cells	40045
nestin-positive	40045
βIII-tubulin-positive transplanted cells	40065
2 months	40121
transplantation	40136
we	40162
the possibility of neural differentiation	40180
the possibility	40180
neural differentiation	40199
the transplanted cells , which might help to bridge the damaged neural circuits	40225
the transplanted cells	40225
the damaged neural circuits	40276
the trophic effects of the transplanted cells on the resident neurons	40305
the trophic effects	40305
the transplanted cells on the resident neurons	40328
the transplanted cells	40328
the resident neurons	40354
functional improvement	40401
neural damage than the possible differentiation of the transplanted cells	40441
neural damage	40441
the possible differentiation of the transplanted cells	40460
the possible differentiation	40460
the transplanted cells	40492
67	40516
OEG and MSC	40526
locomotor function	40551
the spinal cord	40581
their combined advantages	40602
no added benefi t	40636
SCI therapy	40657
Additional treatment	40670
their migration	40723
co-operation	40751
the two types of cells , or different combinations of transplants	40767
the two types of cells	40767
the two types	40767
cells	40784
different combinations of transplants	40794
different combinations	40794
transplants	40820
trophic factors might need to be considered for further functional improvement	40839
trophic factors	40839
further functional improvement	40887
a previous study	40922
the intravenous injection of MSC	40940
the intravenous injection	40940
MSC	40969
the white matter	40980
SCI , but not the gray matter -LRB- 19 -RRB-	41003
SCI	41003
the gray matter -LRB- 19 -RRB-	41016
the gray matter	41016
19	41033
the spared volume	41048
white and gray matter	41069
the intravenous injection	41099
our previous study	41133
the intraspinal injection of MSC used in the current study	41156
the intraspinal injection	41156
MSC used in the current study	41185
MSC	41185
the current study	41197
we	41216
signifi cantly more gray	41225
signifi	41225
intraspinal injection	41275
the spared volume in the control animals	41301
the spared volume	41301
the control animals	41322
100 %	41356
the spared volume of the white matter following intravenous injection	41362
the spared volume	41362
the white matter following intravenous injection	41383
the white matter	41383
intravenous injection	41410
150 % and 134 %	41436
intra spinal injection	41460
the spared volume of the gray matter	41490
the spared volume	41490
the gray matter	41511
137 % following intravenous injection and 220 % following intraspinal injection	41531
137 %	41531
intravenous injection and 220 % following intraspinal injection	41546
intravenous injection	41546
220 % following intraspinal injection	41572
220 %	41572
intraspinal injection	41587
addition	41613
recovery in the BBB test	41623
recovery	41623
the BBB test	41635
the fi rst	41667
few weeks	41678
those animals that received OEG transplants	41705
those animals	41705
OEG transplants	41733
we	41766
the advantageous effects of co-transplantation , direct implantation of OEG	41796
the advantageous effects	41796
co-transplantation , direct implantation of OEG	41824
co-transplantation	41824
direct implantation of OEG	41844
direct implantation	41844
OEG	41867
the spinal cord lesion accompanied by intravenous injection of MSC	41876
the spinal cord lesion	41876
intravenous injection of MSC	41914
intravenous injection	41914
MSC	41939
another , perhaps more effi cacious , approach	41952
the co-transplantation of OEG and MSC	42000
the co-transplantation	42000
OEG and MSC	42026
Acknowledgments	42040
We	42056
James Dutt for critical reading of the manuscript	42065
James Dutt	42065
critical reading of the manuscript	42080
critical reading	42080
the manuscript	42100
This work	42116
the following grants	42143
AVOZ50390703 , IAA500390902 , GACR309/06/1246 , LC554 , 1M0538 and 1A8697-5	42165
The EU FP6 project ENINET -LRB- LSHM-CT-2005 -- 019063 .	42238
The EU FP6 project ENINET -LRB- LSHM-CT-2005	42238
The EU FP6 project	42238
ENINET -LRB- LSHM-CT-2005	42257
019063	42278
Declaration of interest	42286
Declaration	42286
interest	42301
The authors	42311
no confl icts of interest	42330
no confl icts	42330
interest	42347
The authors	42357
the content and writing of the paper	42395
the content and writing	42395
the paper	42422
References 1 .	42434
Verdu E	42448
Garcia-Alias G	42457
Fores J	42473
Gudino-Cabrera G	42482
Muneton VC	42500
Nieto-Sampedro M	42512
et al.	42530
Effects of ensheathing cells	42537
Effects	42537
ensheathing cells	42548
photochemically damaged spinal cord	42584
Neuroreport	42621
2001 ; 12:2303 -- 9 .	42634
2001	42634
12:2303 -- 9	42639
Ramer LM , Au E , Richter MW , Liu J , Tetzlaff W , Roskams AJ .	42653
Ramer LM	42653
Au E , Richter MW , Liu J , Tetzlaff W , Roskams AJ	42663
Au E	42663
Richter MW	42669
Liu J	42681
Tetzlaff W	42688
Roskams AJ	42700
Peripheral olfactory ensheathing cells	42712
scar and cavity formation	42758
regeneration	42796
spinal cord injury	42815
J Comp Neurol .	42835
2004 ; 473:1 -- 15 .	42850
2004	42850
473:1 -- 15	42855
Takami T , Oudega M , Bates ML , Woo PM , Kleitman N , Bunge MB .	42868
Takami T	42868
Oudega M , Bates ML , Woo PM , Kleitman N , Bunge MB	42878
Oudega M	42878
Bates ML	42888
Woo PM	42898
Kleitman N	42906
Bunge MB	42918
Schwann cell but not olfactory ensheathing glia transplants	42928
Schwann cell	42928
Schwann	42928
cell	42936
olfactory ensheathing glia transplants	42949
hindlimb locomotor performance	42996
the moderately contused adult rat thoracic spinal cord	43030
adult rat	43054
J Neurosci .	43086
2002 ; 22:6670 -- 81 .	43098
2002	43098
22:6670 -- 81	43103
Lakatos A , Barnett , SC , Franklin JM .	43118
Lakatos A , Barnett , SC , Franklin	43118
JM	43151
Olfactory ensheathing cells	43155
less host astrocyte response and chondroitin sulphate proteoglycan expression	43190
less host astrocyte response	43190
chondroitin sulphate proteoglycan expression	43223
Schwann cells following transplantation into adult CNS white matter	43273
Schwann cells	43273
transplantation into adult CNS white matter	43297
transplantation	43297
adult CNS white matter	43318
adult CNS	43318
white matter	43328
Exp Neurol .	43342
2003 ; 184:237 -- 46 .	43354
2003	43354
184:237 -- 46	43359
5	43371
Ramon-Cueto A , Avila J. Olfactory ensheathing glia : properties and function .	43374
Ramon-Cueto A , Avila J. Olfactory ensheathing glia	43374
Ramon-Cueto A	43374
Avila J. Olfactory ensheathing glia	43389
Avila J. Olfactory	43389
glia	43420
properties and function	43426
properties	43426
function	43441
Brain Res Bull .	43451
Brain	43451
Res Bull	43457
1998 ; 46:175 -- 87 .	43467
1998	43467
46:175 -- 87	43472
6	43483
Woodhall E , West AK , Chuah MI .	43486
Woodhall E	43486
West AK , Chuah MI	43498
West AK	43498
Chuah MI	43507
olfactory ensheathing cells	43526
nerve	43562
growth factor	43568
brain-derived neurotrophic factor	43583
glia cell line-derived neurotrophic factor	43618
glia cell	43618
line-derived neurotrophic factor	43628
their receptors	43665
Mol Brain Res .	43682
2001 ; 88:203 -- 13 .	43697
2001	43697
88:203 -- 13	43702
7	43713
Au E , Roskams AJ .	43716
Au E	43716
Roskams AJ	43722
Olfactory ensheathing cells of the lamina propria in vivo and in vitro .	43734
Olfactory ensheathing cells	43734
the lamina propria in vivo and in vitro	43765
the lamina propria	43765
vivo	43787
Glia .	43806
2003 ; 41:224 -- 36 .	43812
2003	43812
41:224 -- 36	43817
8	43828
Rojas-Mayorquin AE	43831
Torres-Ruiz NM	43851
Orituno-Sahagun D	43867
Gudino-Cabrera G. Microarray analysis of striatal embryonic stem cells	43886
Gudino-Cabrera G. Microarray analysis	43886
striatal embryonic stem cells	43927
cell conditioned media	43997
cell	43997
media	44014
Dev Dyn .	44021
2008 ; 237:979 -- 94 .	44030
2008	44030
237:979 -- 94	44035
9	44047
Ramon-Cueto A	44050
Nieto-Sampedro M. Regeneration	44065
the spinal cord of transected dorsal root axons	44101
the spinal cord	44101
transected dorsal root axons	44120
glia transplants	44176
Exp Neurol .	44194
1994 ; 127 : 232 -- 44 .	44206
1994 ; 127	44206
232 -- 44	44216
10	44224
Au E , Richter MW , Tetzlaff W , Aebersold R , Sage EH , Roskams AJ .	44228
Au E	44228
Richter MW , Tetzlaff W , Aebersold R , Sage EH , Roskams AJ	44234
Richter MW	44234
Tetzlaff W	44246
Aebersold R	44258
Sage EH	44271
Roskams AJ	44280
SPARC from olfactory ensheathing cells	44292
SPARC	44292
olfactory ensheathing cells	44303
Schwann cells	44342
neurite outgrowth	44367
spinal cord repair	44398
J Neurosci .	44418
2007 ; 27:7208 -- 21 .	44430
2007	44430
27:7208 -- 21	44435
11	44447
Caplan AI .	44451
Adult mesenchymal stem cells	44462
tissue engineering	44495
regenerative medicine	44521
J Cell Physiol .	44544
2007 ; 213:341 -- 7 .	44560
2007	44560
213:341 -- 7	44566
12	44577
Caplan AI , Dennis JE .	44581
Caplan AI	44581
Dennis JE	44592
Mesenchymal stem cells as trophic mediators .	44603
Mesenchymal stem cells	44603
trophic mediators	44629
J Cell Biochem .	44648
J Cell	44648
Biochem	44655
2006 ; 93:1076 -- 84 .	44664
2006	44664
93:1076 -- 84	44669
13	44681
Opydo-Canek M. Bone marrow stromal cells in traumatic brain injury therapy	44685
Opydo-Canek M. Bone marrow	44685
stromal cells in traumatic brain injury therapy	44712
stromal cells	44712
traumatic brain injury therapy	44729
true perspective or false hope	44761
true perspective	44761
false hope	44781
Acta Neurobiol Exp .	44793
2007 ; 67:187 -- 95 .	44813
2007	44813
67:187 -- 95	44818
14	44829
Chen L , Tredget EE , Wu PYG , Wu Y. Paracrine factors of mesenchymal stem cells	44833
Chen L , Tredget EE , Wu PYG , Wu Y. Paracrine factors	44833
mesenchymal stem cells	44888
macrophages and endothelial lineage cells	44919
macrophages	44919
endothelial lineage cells	44935
wound healing	44973
PloS One .	44988
PloS	44988
One	44993
2008 ; 3 : e1886 .	44998
2008	44998
3 : e1886	45003
15	45012
Dasari VR , Spomar DG , Cady C , Gujrati M , Rao JS , Dinh DH .	45016
Dasari VR	45016
Spomar DG , Cady C , Gujrati M , Rao JS , Dinh DH	45027
Spomar DG	45027
Cady C	45038
Gujrati M	45046
Rao JS	45057
Dinh DH	45065
Mesenchymal stem cells from rat bone marrow	45074
Mesenchymal stem cells	45074
rat bone marrow	45102
caspase-3-mediated apoptotic pathway	45131
spinal cord injury in rats	45174
spinal cord injury	45174
rats	45196
Neurochem Res .	45202
2007 ; 32:2080 -- 93 .	45217
2007	45217
32:2080 -- 93	45222
16	45234
Ucelli A	45238
Moretta L	45248
Pistoia V. Immunoregulatory function of mesenchymal stem cells	45259
Pistoia V. Immunoregulatory function	45259
mesenchymal stem cells	45299
Eur J Immunol .	45323
2006 ; 36:2566 -- 73 .	45338
2006	45338
36:2566 -- 73	45343
17	45355
Pedemonte E	45359
Benvenuto F , Casazza S , Mancardi G , Oksenberg JR , Uccelli A , et al.	45372
Benvenuto F	45372
Casazza S	45385
Mancardi G	45396
Oksenberg JR	45408
Uccelli A	45422
et al.	45433
The molecular signature of therapeutic mesenchymal stem cells	45440
The molecular signature	45440
therapeutic mesenchymal stem cells	45467
the architecture of the hematopoietic stem cell niche synapse	45510
the architecture	45510
the hematopoietic stem cell niche synapse	45530
BMC Genomics	45573
2007 ; 8:65 .	45587
2007	45587
8:65	45592
18	45598
Sykova E , Jendelova P .	45602
Sykova	45602
E , Jendelova P	45609
E	45609
Jendelova P	45612
In vivo tracking of stem cells in brain and spinal cord injury .	45625
In vivo tracking	45625
stem cells	45645
brain and spinal cord injury	45659
Prog Brain Res .	45689
Prog Brain	45689
Res	45700
2007 ; 161:367 -- 83 .	45705
2007	45705
161:367 -- 83	45710
19	45722
Urdzikova L	45726
Jendelova P	45739
Glogarova K	45752
Burian M	45765
Hajek M	45775
Sykova E. Transplantation	45784
bone marrow stem cells	45813
mobilization by granulocyte-colony stimulating factor	45847
mobilization	45847
granulocyte-colony stimulating factor	45863
recovery	45910
spinal cord injury in rats	45925
spinal cord injury	45925
rats	45947
J Neurotrauma .	45953
2006 ; 23:1379 -- 91 .	45968
2006	45968
23:1379 -- 91	45973
20	45985
Hofstetter CP	45989
Schwarz EJ , Hess D , Widenfalk J , Manira AE , Prockop DJ , et al.	46004
Schwarz EJ	46004
Hess D	46016
Widenfalk J	46024
Manira AE	46037
Prockop DJ	46048
et al.	46060
Marrow stromal cells	46067
guiding strands	46093
the injured spinal cord	46112
recovery	46148
Proc Natl Acad Sci USA .	46158
2002 ; 99:2199 -- 204 .	46182
2002	46182
99:2199 -- 204	46187
21	46200
Vanicky I , Urdzikova L , Saganova K , Cizkova D , Galik J .	46204
Vanicky I	46204
Urdzikova L	46215
Saganova K	46228
Cizkova D	46240
Galik J	46251
A simple and reproducible model of spinal cord injury	46260
A simple and reproducible model	46260
spinal cord injury	46295
epidural balloon infl ation in the rat	46325
epidural balloon infl ation	46325
the rat	46356
J Neurotrauma .	46365
2001 ; 18:1399 -- 407 .	46380
2001	46380
18:1399 -- 407	46385
22	46398
Sedy J , Urdzikova L , Likavcanova K , Hejcl A , Jendelova P , Sykova Y .	46402
Sedy J	46402
Urdzikova L	46410
Likavcanova K	46423
Hejcl A	46438
Jendelova P	46447
Sykova Y	46460
Sykova	46460
Y	46467
A new model of severe neurogenic pulmonary edema in spinal cord injured rat .	46470
A new model	46470
severe neurogenic pulmonary edema	46485
spinal cord injured rat	46522
Neurosci Lett .	46547
2007 ; 423 : 167 -- 71 .	46562
2007 ; 423	46562
167 -- 71	46572
23	46580
Bianco JI , Perry C , Harkin DG , Mackay-Sim A , Feron F. Neurotrophin 3	46584
Bianco JI	46584
Perry C	46595
Harkin DG	46604
Mackay-Sim A	46615
Feron F. Neurotrophin 3	46629
Feron F. Neurotrophin	46629
3	46651
purifi cation and proliferation of olfactory ensheathing cells	46662
purifi cation and proliferation	46662
olfactory ensheathing cells	46697
human nose	46730
Glia .	46742
2004 ; 45:111 -- 23 .	46748
2004	46748
45:111 -- 23	46754
24	46765
Woodhall E , West AK , Vickers AK , Chuah MI .	46769
Woodhall E	46769
West AK	46781
Vickers AK	46790
Chuah MI	46802
Olfactory ensheathing cell phenotype	46812
implantation in the lesioned spinal cord	46859
implantation	46859
the lesioned spinal cord	46875
Cell Mol Life Sci .	46901
Cell	46901
Mol Life Sci	46906
2003 ; 60:2241 -- 53 .	46920
2003	46920
60:2241 -- 53	46925
25	46937
Azizi SA , Stokes D , Augelli BJ , Digirolamo C , Prockop DJ .	46941
Azizi SA	46941
Stokes D	46951
Augelli BJ	46961
Digirolamo C	46973
Prockop DJ	46987
Engraftment	46999
migration	47015
human bone marrow stromal cells	47028
the brains of albino rats	47073
the brains	47073
albino rats	47087
similarities to astrocyte grafts	47100
similarities	47100
astrocyte grafts	47116
Proc Natl Acad Sci USA .	47134
1998 ; 95:3908 -- 18 .	47158
1998	47158
95:3908 -- 18	47163
26	47175
Imaizumi T , Lankford KL , Kocsis JD .	47179
Imaizumi T	47179
Lankford KL , Kocsis JD	47191
Lankford KL	47191
Kocsis JD	47204
Transplantation of olfactory ensheathing cells or Schwann cells	47215
Transplantation	47215
olfactory ensheathing cells or Schwann cells	47234
rapid and secure conduction	47288
the transected spinal cord	47323
Brain Res .	47351
Brain	47351
Res	47357
2000 ; 854:70 -- 8 .	47362
2000	47362
854:70 -- 8	47367
27	47377
Li X , Dancausse H , Grijalva I , Oliveira M , Levi DO .	47381
Li X	47381
Dancausse H	47387
Grijalva I , Oliveira M	47400
Levi DO	47424
Schwann cells	47442
CFSE : an in vitro and in vivo study	47461
CFSE	47461
an in vitro and in vivo study	47467
vivo	47486
J Neurosci Methods .	47498
J Neurosci	47498
Methods	47509
2003 ; 125:83 -- 91 .	47518
2003	47518
125:83 -- 91	47523
28	47534
Okabe M	47538
Ikawa M	47547
Kominami K	47556
Nakanishi T , Nishimune Y. Green mice as a source of ubiquitous green cells	47568
Nakanishi T , Nishimune Y. Green mice	47568
a source of ubiquitous green cells	47608
a source	47608
ubiquitous green cells	47620
FASEB Lett .	47644
1977 ; 407:313 -- 9 .	47656
1977	47656
407:313 -- 9	47661
29	47672
Basso DM , Beattie MS , Bresnahan JC .	47676
Basso DM	47676
Beattie MS , Bresnahan JC	47686
Beattie MS	47686
Bresnahan JC	47698
A sensitive and reliable locomotor rating scale for open fi	47712
A sensitive and reliable locomotor rating scale	47712
open fi	47764
testing	47776
rats	47787
J Neurotrauma .	47793
1995 ; 12:1 -- 12 .	47808
1995	47808
12:1 -- 12	47813
30	47822
Sykova	47826
E , Homola A , Mazanec R , Lachman H , Konradova SL , Kobylka P , et al.	47833
E	47833
Homola A	47836
Mazanec R	47846
Lachman H	47857
Konradova SL	47868
Kobylka P	47882
et al.	47893
Autologous bone marrow transplantation	47900
patients	47942
subacute and chronic spinal cord injury	47956
subacute	47956
chronic spinal cord injury	47969
Cell Transplant .	47997
Cell	47997
Transplant	48002
2006 ; 15:675 -- 87 .	48014
2006	48014
15:675 -- 87	48019
31	48030
Parr AM , Kulbatski I , Tator CH .	48034
Parr AM	48034
Kulbatski I	48043
Kulbatski	48043
I	48053
Tator CH	48056
Transplantation	48066
adult rat spinal cord stem/progenitor cells	48085
spinal cord injury	48133
J Neurotrauma .	48153
2007 ; 24:835 -- 45 .	48168
2007	48168
24:835 -- 45	48173
32	48184
Park E , Velumian AA , Fehlings MG .	48188
Park E	48188
Velumian AA , Fehlings MG	48196
Velumian AA	48196
Fehlings MG	48209
The role of excitatoxicity in secondary mechanisms of spinal cord injury	48222
The role	48222
excitatoxicity in secondary mechanisms of spinal cord injury	48234
excitatoxicity	48234
secondary mechanisms of spinal cord injury	48252
secondary mechanisms	48252
spinal cord injury	48276
a review with an emphasis on the implications for white matter degeneration	48296
a review	48296
an emphasis on the implications for white matter degeneration	48310
an emphasis	48310
the implications for white matter degeneration	48325
the implications	48325
white matter degeneration	48346
J Neurotrauma .	48373
2004 ; 21:754 -- 74 .	48388
2004	48388
21:754 -- 74	48393
33	48404
Rowland JW , Hawryluk GWJ , Kwon B , Fehlings MG .	48408
Rowland JW	48408
Hawryluk GWJ	48420
Kwon B	48434
Fehlings MG	48442
Current status	48455
acute spinal cord injury pathophysiology and emerging therapies	48473
promise on the horizon	48538
promise	48538
the horizon	48549
Neurosurg Focus .	48562
2008 ; 25 -LSB- 5 -RSB- : e2 .	48579
2008 ; 25 -LSB- 5 -RSB-	48579
2008 ; 25	48579
5 -RSB-	48587
e2	48590
34	48594
Rolls A	48598
Shechter R , Londong A , Segev Y , Jacob-Hirsch J , Amariglio N , et al.	48607
Shechter R	48607
Londong A	48619
Segev Y	48630
Jacob-Hirsch J	48639
Amariglio N	48655
et al.	48668
Two faces of chondroitin sulfate proteoglycan in spinal cord repair	48675
Two faces	48675
chondroitin sulfate proteoglycan in spinal cord repair	48688
chondroitin sulfate proteoglycan	48688
spinal cord repair	48724
a role in microglia/macrophage activation	48744
a role	48744
microglia/macrophage activation	48754
PLoS Med .	48787
2008 ; 5 : e171 .	48797
2008	48797
5 : e171	48802
35	48810
Morino T , Ogata T , Horiuchi H , Takeba J , Okumura H , Miyazaki T , et al. .	48814
Morino T	48814
Ogata T , Horiuchi H , Takeba J , Okumura H , Miyazaki T , et al.	48824
Ogata T	48824
Horiuchi H	48833
Takeba J	48845
Okumura H	48855
Miyazaki T	48866
et al.	48878
Delayed neuronal dagame	48885
microglia proliferation	48920
mild spinal cord compression injury	48950
Neurosci Res .	48987
2003 ; 46:309 -- 18 .	49001
2003	49001
46:309 -- 18	49006
36	49017
Richter MW , Fletcher PA , Liu J , Tetzlaff W , Roskams AJ .	49021
Richter MW	49021
Fletcher PA	49033
Liu J	49046
Tetzlaff W	49053
Roskams AJ	49065
Lamina propria and olfactory bulb ensheathing cells	49077
Lamina propria	49077
olfactory bulb ensheathing cells	49096
differential integration and migration	49137
differential axon sprouting in the lesioned spinal cord	49188
differential axon	49188
the lesioned spinal cord	49219
J Neurosci .	49245
2005 ; 25:10700 -- 11 .	49257
2005	49257
25:10700 -- 11	49262
37	49275
Uccelli A , Pistia V , Moretta L. Mesenchymal stem cells	49279
Uccelli A	49279
Pistia V	49290
Moretta L. Mesenchymal stem cells	49300
Moretta L.	49300
Mesenchymal stem cells	49311
a new strategy for immunosuppression	49335
a new strategy	49335
immunosuppression	49354
Trends Immunol .	49373
Trends	49373
Immunol	49380
2007 ; 28:219 -- 26 .	49389
2007	49389
28:219 -- 26	49394
38	49405
Sordi V	49409
Malosio ML , Marchesi , F , Mercalli A , Melzi R , Giordano T , et al.	49418
Malosio ML	49418
Marchesi	49430
F	49440
Mercalli A	49443
Melzi R	49455
Giordano T	49464
et al.	49476
Bone marrow mesenchymal cells	49483
a restricted set of functionally active chemokine receptors	49521
a restricted set	49521
functionally active chemokine receptors	49541
migration	49602
pancreatic islets	49615
Blood 2005 ; 106:419 -- 27 .	49634
Blood 2005	49634
106:419 -- 27	49645
39	49657
Lu P , Yang H , Culbertson M , Graham L , Roskams AJ , Tuszynski MH .	49661
Lu P	49661
Yang H , Culbertson M , Graham L , Roskams AJ , Tuszynski MH	49667
Yang H	49667
Culbertson M	49675
Graham L	49689
Roskams AJ	49699
Tuszynski MH	49711
Olfactory ensheathing cells	49725
unique migratory or axonal growth-promoting properties after spinal cord injury	49768
unique migratory or axonal growth-promoting properties	49768
spinal cord injury	49829
J Neurosci .	49849
2006 ; 26:11120 -- 30 .	49861
2006	49861
26:11120 -- 30	49866
40	49879
Su Z , Cao L , Zhu Y , Liu X , Huang Z , Huang A , et al. .	49883
Su	49883
Z , Cao L , Zhu Y , Liu X , Huang Z , Huang A , et al.	49886
Z	49886
Cao L	49889
Zhu Y	49896
Liu X	49903
Huang Z	49910
Huang A	49919
et al.	49928
Nogo	49935
the adhesion of olfactory ensheathing cells	49949
the adhesion	49949
olfactory ensheathing cells	49965
their migration	50006
J Cell Sci .	50023
J Cell	50023
Sci	50030
2007 ; 120:1877 -- 87 .	50035
2007	50035
120:1877 -- 87	50040
41	50053
Dubreuil CI	50057
Winton MJ	50070
McKerracher L. Rho activation patterns after spinal cord injury	50081
McKerracher L. Rho activation patterns	50081
spinal cord injury	50126
the role of activated Rho in apoptosis in the central nervous system	50149
the role	50149
activated Rho in apoptosis in the central nervous system	50161
activated Rho	50161
apoptosis in the central nervous system	50178
apoptosis	50178
the central nervous system	50191
J Cell Biol .	50219
2003 ; 162:233 -- 43 .	50232
2003	50232
162:233 -- 43	50237
42	50249
Madura T	50253
Yamashita T	50263
Kubo T. Activation of Rho in the injured axons following spinal cord injury	50276
Kubo T. Activation	50276
Rho in the injured axons following spinal cord injury	50298
Rho	50298
the injured axons following spinal cord injury	50305
the injured axons	50305
spinal cord injury	50333
EMBO Rep. 2004 ; 5:412 -- 7 .	50353
EMBO Rep. 2004	50353
5:412 -- 7	50368
43	50377
Meriane M , Duhamel S , Lejeune L , Galipeau J , Annabi B , et al. .	50381
Meriane M	50381
Duhamel S , Lejeune L , Galipeau J , Annabi B , et al.	50392
Duhamel S	50392
Lejeune L	50403
Galipeau J	50414
Annabi B	50426
et al.	50436
Cooperation	50443
matrix metalloproteinases	50458
the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1	50489
the RhoA/Rho kinase	50489
mitogen-activated protein kinase kinase-1	50513
extracellular signal-regulated kinase signaling pathways	50555
the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells	50628
the sphingosine-1-phosphate-induced mobilization	50628
marrow-derived stromal cells	50680
Stem Cells .	50710
2006 ; 24:2557 -- 65 .	50722
2006	50722
24:2557 -- 65	50727
44	50739
Jaganathan BG , Ruester B , Dressel L , Stein S , Grez M , Seifried E , et al. .	50743
Jaganathan BG	50743
Ruester B , Dressel L , Stein S , Grez M , Seifried E , et al.	50758
Ruester B	50758
Dressel L	50769
Stein S	50780
Grez M	50789
Seifried E	50797
et al.	50809
Rho inhibition	50816
migration of mesenchymal stromal cells	50839
migration	50839
mesenchymal stromal cells	50852
Stem Cells .	50879
2007 ; 25:1966 -- 74 .	50891
2007	50891
25:1966 -- 74	50896
45	50908
McKerracher L	50912
Higuchi H. Targeting Rho to stimulate repair after spinal cord injury	50927
Higuchi H. Targeting Rho	50927
repair	50965
spinal cord injury	50978
J Neurotrauma .	50998
2006 ; 23:309 -- 17 .	51013
2006	51013
23:309 -- 17	51018
46	51029
Fouad K , Pedersen V , Schwab ME .	51033
Fouad K	51033
Pedersen V , Schwab ME	51042
Pedersen V	51042
Schwab ME	51054
Cervical sprouting of corticospinal fi bers after thoracic spinal cord injury	51065
Cervical	51065
corticospinal fi bers	51087
thoracic spinal cord injury	51115
shifts	51155
motor responses	51172
Curr Biol .	51189
2001 ; 11:1766 -- 70 .	51200
2001	51200
11:1766 -- 70	51206
47	51218
Deumens R , Koopmans GC , Joosten EAJ .	51222
Deumens R	51222
Koopmans GC , Joosten EAJ	51233
Koopmans GC	51233
Joosten EAJ	51246
Regeneration of descending axon tracts spinal cord injury .	51259
Regeneration	51259
descending axon tracts spinal cord injury	51275
descending axon tracts	51275
spinal cord injury	51298
Prog Neurobiol .	51318
Prog	51318
Neurobiol	51323
2005 ; 77:57 -- 89 .	51334
2005	51334
77:57 -- 89	51339
48	51349
Steward O , Zheng B , Tessier-Lavigne M , Hofstdter M , Sharp K , Yee KM .	51353
Steward O	51353
Zheng B , Tessier-Lavigne M , Hofstdter M , Sharp K , Yee KM	51364
Zheng B	51364
Tessier-Lavigne M	51373
Hofstdter M	51392
Sharp K	51405
Yee KM	51414
Regeneration beyond the glial scar .	51422
Regeneration	51422
the glial scar	51442
J Neurosci .	51458
2008 ; 28:6836 -- 47 .	51470
2008	51470
28:6836 -- 47	51475
49	51487
Bareyre FM	51491
Kerschensteiner M , Raineteau O , Mettenleiter TC , Weinmann O , Schwab ME	51503
Kerschensteiner M	51503
Raineteau O	51522
Mettenleiter TC	51535
Weinmann O	51552
Schwab ME	51564
The injured spinal cord	51575
a new intraspinal circuits in adult rats	51619
a new intraspinal circuits	51619
adult rats	51649
Nat Neurosci .	51661
2004 ; 7:269 -- 77 .	51675
2004	51675
7:269 -- 77	51680
50	51690
Courtine G , Song B , Roy RR , Zhong H , Hermann JE , Ao Y , et al. .	51694
Courtine G	51694
Song B , Roy RR , Zhong H , Hermann JE , Ao Y , et al.	51706
Song B	51706
Roy RR	51714
Zhong H	51722
Hermann JE	51731
Ao Y	51743
et al.	51749
Recovery	51756
supraspinal control	51768
indirect propriospinal relay connections	51804
spinal cord injury	51851
Nat Med .	51871
2008 ; 14:69 -- 74 .	51880
2008	51880
14:69 -- 74	51885
51	51895
Oria M , Chatauret N , Raguer N , Cordoba J .	51899
Oria M	51899
Chatauret N	51907
Raguer N	51920
Cordoba J	51930
A new method for measuring motor	51941
A new method	51941
motor	51968
potentials	51981
the awake rat : effects of anesthetics	51995
the awake rat	51995
effects of anesthetics	52010
effects	52010
anesthetics	52021
J Neurotrauma .	52034
2008 ; 25:266 -- 75 .	52049
2008	52049
25:266 -- 75	52054
52	52065
Ondrejcak T , Vanicky I , Galik J , Saganova K.	52069
Ondrejcak T	52069
Vanicky I , Galik J , Saganova K.	52082
Vanicky I , Galik J	52082
Saganova K.	52102
electrodes	52136
repeated stimulation and recording of spinal cord potentials	52151
repeated stimulation and recording	52151
spinal cord potentials	52189
J Neurosci Methods .	52213
J Neurosci	52213
Methods	52224
2005 ; 141:125 -- 34 .	52233
2005	52233
141:125 -- 34	52238
53	52250
Smith HC , Savic G , Frankel HL , Ellawa PH , Maskill DW , Jamous MA , et al. .	52254
Smith HC	52254
Savic G , Frankel HL , Ellawa PH , Maskill DW , Jamous MA , et al.	52264
Savic G	52264
Frankel HL	52273
Ellawa PH	52285
Maskill DW	52296
Jamous MA	52308
et al.	52319
Corticospinal function	52326
time following incomplete spinal cord injury	52362
time	52362
incomplete spinal cord injury	52377
Spinal Cord .	52408
2000 ; 38:292 -- 300 .	52421
2000	52421
38:292 -- 300	52427
54	52439
Fehlings MG , Tator CH .	52443
Fehlings MG	52443
Tator CH	52456
The relationships	52466
the severity	52490
spinal cord injury	52506
residual neurological function	52526
axon counts	52558
counts of retrogradely	52575
counts	52575
retrogradely	52585
neurons	52606
experimental spinal cord injury	52620
Exp Neurol .	52653
1995 ; 132:220 -- 8 .	52665
1995	52665
132:220 -- 8	52671
55	52682
Totoiu MO , Keirstead HS .	52686
Totoiu MO	52686
Keirstead HS	52697
Spinal cord injury	52711
chronic progressive demyelination	52748
J Comp Neurol .	52783
2005 ; 486:373 -- 83 .	52798
2005	52798
486:373 -- 83	52803
56	52815
Siegenthaler MM , Tu MK , Keirstead HS .	52819
Siegenthaler MM	52819
Tu MK , Keirstead HS	52836
Tu MK	52836
Keirstead HS	52843
The extent of myelin pathology	52857
The extent	52857
myelin pathology	52871
contusion and transection spinal cord injury	52906
J Neurotrauma .	52952
2007 ; 24:1631 -- 46 .	52967
2007	52967
24:1631 -- 46	52972
57	52984
Franklin RJM .	52988
Remyelination by transplanted olfactory ensheathing cells .	53002
Remyelination	53002
transplanted olfactory ensheathing cells	53019
transplanted olfactory ensheathing	53019
cells	53054
Anat Rec B New Anat .	53061
2003 ; 271:71 -- 6 .	53082
2003	53082
271:71 -- 6	53087
58	53097
Boyd JG , Doucette R , Kawaja MD. .	53101
Boyd JG	53101
Doucette R , Kawaja MD.	53110
Doucette R	53110
Kawaja MD.	53122
Defi	53133
the role of the olfactory ensheathing cells	53143
the role	53143
the olfactory ensheathing cells	53155
axon remyelination following damage to the spinal cord	53203
axon remyelination	53203
damage to the spinal cord	53232
damage	53232
the spinal cord	53242
FASEB J. 2005 ; 19 : 694 -- 703 .	53259
FASEB J. 2005 ; 19	53259
FASEB J.	53259
2005 ; 19	53268
694 -- 703	53277
59	53286
Raineteau O , Schwab ME .	53290
Raineteau O	53290
Schwab ME	53303
Plasticity of motor systems after incomplete spinal cord injury .	53314
Plasticity	53314
motor systems	53328
incomplete spinal cord injury	53348
Nat Rev Neurosci .	53379
Nat Rev	53379
Neurosci	53387
2001 ; 2:263 -- 73 .	53397
2001	53397
2:263 -- 73	53403
60	53413
Le Blanc K	53417
Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience	53429
Ringden O. Immunomodulation	53429
mesenchymal stem cells and clinical experience	53460
mesenchymal stem cells	53460
clinical experience	53487
J Intern Med .	53508
2007 ; 262:509 -- 25 .	53522
2007	53522
262:509 -- 25	53527
61	53539
Firouzi M	53543
Mashayedi P , Saberi H , Mobasheri H , Abolhassani F , Jahanzad I , et al.	53554
Mashayedi P	53554
Saberi H	53567
Mobasheri H	53577
Abolhassani F	53590
Jahanzad I	53605
Jahanzad	53605
I	53614
et al.	53617
Transplantation of Schwann cells to subarachnoid space	53624
Transplantation	53624
Schwann cells to subarachnoid space	53643
Schwann cells	53643
subarachnoid space	53660
repair in contused rat spinal cord	53687
repair	53687
contused rat spinal cord	53697
Neurosci Lett .	53723
2006 ; 402:66 -- 70 .	53738
2006	53738
402:66 -- 70	53743
62	53754
Lin CR , Wu PC , Shih HC , Cheng JT , Lu CY , Chou AK , et al. .	53758
Lin CR	53758
Wu PC , Shih HC , Cheng JT , Lu CY , Chou AK , et al.	53766
Wu PC	53766
Shih HC	53773
Cheng JT	53782
Lu CY	53792
Chou AK	53799
et al.	53808
Intrathecal spinal progenitor	53815
cell transplantation for the treatment of neurotrophic pain	53845
cell transplantation	53845
the treatment of neurotrophic pain	53870
the treatment	53870
neurotrophic pain	53887
Cell Transplant .	53906
Cell	53906
Transplant	53911
2002 ; 11:17 -- 24 .	53923
2002	53923
11:17 -- 24	53929
63	53939
Ohta M , Suzuki Y , Noda T , Ejiri Y , Dezawa M , Kataoka K , et al. .	53943
Ohta M	53943
Suzuki Y , Noda T , Ejiri Y , Dezawa M , Kataoka K , et al.	53951
Suzuki Y	53951
Noda T	53961
Ejiri Y	53969
Dezawa M	53978
Kataoka K	53988
et al.	53999
Bone marrow stromal infused into the cerebrospinal fl uid	54006
Bone marrow stromal	54006
Bone marrow	54006
the cerebrospinal fl uid	54039
functional recovery of the injured rat spinal cord	54072
functional recovery	54072
the injured rat spinal cord	54095
reduced cavity formation	54128
Exp Neurol .	54154
2004 ; 187 : 266 -- 78 .	54166
2004 ; 187	54166
266 -- 78	54176
64	54184
Pittenger MF	54188
Mackay AM , Beck SC , Jaiswal RK , Douglas R , Mosca JD , et al.	54202
Mackay AM	54202
Beck SC	54213
Jaiswal RK	54222
Douglas R	54234
Mosca JD	54245
et al.	54255
Multilineage potential of adult human mesenchymal stem cells .	54262
Multilineage potential	54262
adult human mesenchymal stem cells	54288
Science .	54324
1998 ; 284:143 -- 7 .	54333
1998	54333
284:143 -- 7	54338
65	54349
Lu P , Blesch A , Tuszynski MH .	54353
Lu P	54353
Blesch A , Tuszynski MH	54359
Blesch A	54359
Tuszynski MH	54369
Induction of bone marrow stromal cells to neurons	54383
Induction	54383
bone marrow stromal cells	54396
neurons	54425
differentiation , transdifferentiation , or artifact	54434
differentiation	54434
transdifferentiation	54451
artifact	54476
J Neurosci Res .	54486
2004 ; 77:174 -- 91 .	54502
2004	54502
77:174 -- 91	54507
66	54518
Krabbe C , Zimmer J , Meyer M.	54522
Krabbe C	54522
Zimmer J	54532
Meyer M.	54542
Neural	54551
trasndifferentiation of mesenchymal stem cells	54558
trasndifferentiation	54558
mesenchymal stem cells	54582
a critical review	54606
APMIS .	54625
2005 ; 113:831 -- 44 .	54632
2005	54632
113:831 -- 44	54638
67	54650
Ross JJ , Verfaillie CM .	54654
Ross JJ	54654
Verfaillie CM	54663
Evaluation of neural plasticity in adult stem cells .	54678
Evaluation	54678
neural plasticity	54692
adult stem cells	54713
Philos Trans R Sco Lond B Biol Sci .	54731
2008 ; 363 : 199 -- 205 .	54767
2008 ; 363	54767
199 -- 205	54777
